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ABSTRACT 
Background: Myotonic dystrophy type 1(DM1) is an inherited, slowly progressive, 
multi-system disease. There is no overall picture of its effect in individuals, and there is 
a lack of scientific evidence to support recommendations on physical exercise. 
Aim: The aims of the work described in this thesis were to explore aspects of 
functioning, disability and contextual factors in adults with DM1 with regard to 
different stages of the disease; to describe the reliability and feasibility of the six-
minute-walk test (6MWT), and to evaluate the feasibility and effects of a physical 
exercise programme.  
Methods: Seventy adults with DM1 were assessed using various methods and 
measures, including a modified ICF checklist, tests and questionnaires. The reliability 
of the 6MWT was evaluated in 12 persons with DM1, and its feasibility in another 64. 
A comprehensive group exercise training programme, the Friskis&Svettis® Open 
Doors programme, was evaluated in 35 adults with DM1. They were assigned by lot to 
either a training group (18 persons) or a control group (17 persons). The training group 
participated in the exercise programme for 60 minutes twice a week during 14 weeks. 
The 6MWT was the primary outcome measure. Stages of disease progression were in 
all the studies based on the disease-specific muscular impairment rating scale. 
Results: Excessive daytime sleepiness, muscle weakness and fatigue were common 
body-function impairments. Activity limitations were most frequently found in 
physically-demanding mobility activities. Few reported participation restrictions. 
Support from the immediate family was the most important facilitator for functioning. 
The individual’s total number of impairments, limitations and restrictions was high and 
persons with severe muscular impairment had more impairments and 
limitations/restrictions than did those with mild. The 6MWT was reliable and feasible. 
The better of two possible trials was identified for use as test result. A difference of 33 
metres or 6% for an individual with DM1 for a change not to be ascribed to 
measurement error is suggested .The Open Doors programme was well tolerated and no 
detrimental effects were found. Intention-to-treat analyses revealed no significant 
between-group differences in the primary outcome measure. Six persons in the training 
group and two controls increased their 6MWT distance by ≥6%. Many participants in 
the training group experienced subjective improvements and could recommend this 
form of physical exercise to others with the same disease 
Conclusion: The finding of a wide variety of body-function impairments, activity 
limitations and participation restrictions underlines the multi-systemic nature of the 
disease and the vast impact it has on health. It further implies that a multi-professional 
approach is needed for optimal care. The information can be used for developing 
clinical practice and for health promotion for people with DM1. The 6MWT was 
reliable and feasible, and can be used as an outcome measure in adults with DM1. The 
Friskis&Svettis® Open Doors programme was feasible for adults with DM1 who had 
been screened for cardiac involvement, had distal or mild-to-moderate proximal muscle 
impairment and no severe cognitive impairments.  
Keywords: classification, disability, functioning, ICF, myotonic dystrophy, 
physiotherapy, physical exercise, rehabilitation, reliability 
  
SAMMANFATTNING 
Bakgrund: Dystrofia myotonika typ 1 (DM1) är en ärftlig, långsamt progressiv 
multisystemsjukdom. Det saknas en samlad bild av de effekter sjukdomen har på 
individer, och det råder en brist på vetenskaplig evidens för rekommendationer gällande 
fysisk träning vid DM1. 
Syfte: Avhandlingens syfte var att undersöka aspekter av funktionstillstånd, 
funktionshinder och kontextuella faktorer hos vuxna med DM1 med hänsyn till olika 
stadier av sjukdomen; att beskriva reliabilitet och genomförbarhet av sex minuters 
gångtest (6MWT), och att utvärdera genomförbarhet och effekter av ett fysiskt 
träningsprogram. 
Metod: Sjuttio vuxna med DM1 bedömdes med hjälp av olika metoder, bl.a. en 
modifierad ICF checklista och olika tester och frågeformulär. I undersökningen av 
reliabilitet och genomförbarhet av 6MWT ingick 12 respektive 64 personer med DM1. 
För att utvärdera ett allsidigt program för motionsträning i grupp, Friskis & Svettis ® 
Öppna dörrar, lottades 35 vuxna med DM1 till antingen en träningsgrupp (18 personer) 
eller en kontrollgrupp (17 personer). Träningsgruppen deltog i motionsträning i 60 min, 
två ggr/vecka under 14 veckor. Den primära effektvariabeln var 6MWT. Den 
diagnosspecifika skalan ”muscular impairment rating scale” användes i alla studier för 
att beskriva olika stadier av sjukdomen. 
Resultat: Dagtrötthet, muskelsvaghet och fatigue var vanligt förkommande 
funktionsnedsättningar. Aktivitetsbegränsningar förekom oftast i fysiskt krävande 
aktiviteter inom ICF-domänen förflyttning. Få personer uppgav 
delaktighetsinskränkningar. Stöd från närstående var den viktigaste underlättande 
omgivningsfaktorn. Det sammanlagda antalet funktionsnedsättningar, 
aktivitetsbegränsningar och delaktighetsinskränkningar per individ var högt, och 
personer med svår grad av sjukdomen hade fler nedsättningar och 
begränsningar/inskränkningar än de med mild grad. Testet 6MWT var reliabelt och 
genomförbarheten var god. Det bästa av två försök ska användas som testresultat. För 
en individ med DM1 föreslås en skillnad på 33 meter eller 6% överstiga mätmetodfelet. 
Motionsträningen tolererades väl och det förekom inga skadeverkningar. Det var ingen 
skillnad mellan grupperna avseende den primära effektvariabeln, 6MWT. Sex personer 
i träningsgruppen och två kontroller ökade sin 6MWT gångsträcka med ≥ 6%. Många 
deltagare i träningsgruppen upplevde subjektiva förbättringar och kunde rekommendera 
denna form av träning till andra med samma sjukdom.  
Slutsats: Fynden av en mängd olika funktionsnedsättningar, aktivitetsbegränsningar 
och delaktighetsinskränkningar understryker att DM1 är en multisystemsjukdom som 
har stor inverkan på hälsan. Resultatet indikerar vidare att ett multiprofessionellt 
förhållningssätt krävs för optimal vård. Informationen kan användas för att utveckla 
klinisk praxis och för hälsofrämjande arbete för individer med DM1. Testet 6MWT var 
reliabelt, och kan användas som ett utvärderingstest hos vuxna med DM1. Friskis & 
Svettis ® Öppna dörrar-program var lämpligt för vuxna med DM1 som hade 
undersökts avseende hjärtfunktion, hade distal eller mild till måttlig proximal 
muskelsvaghet och inga svåra kognitiva funktionsnedsättningar. 
Nyckelord: klassifikation, funktionshinder, funktionstillstånd, ICF, dystrofia 
myotonika, sjukgymnastik, fysisk träning, rehabilitering, reliabilitet 
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1 BACKGROUND 
1.1 INTRODUCTION 
Imagine you had a disease that slowly made you weaker and weaker. That weakness 
and wasting first affected muscles in your face, neck, hands and feet, making it difficult 
for you to do ordinary daily things like opening a jar, carrying home your groceries, 
climbing the stairs or running to the bus. Wouldn’t you like to know whether physical 
exercise was good for you? Well, I would! 
The scenario just described could be the one for a person with myotonic dystrophy type 
1, the most common form of inherited muscular dystrophy in adults. As a 
physiotherapist, working at the Neurological Physical Therapy Department at 
Karolinska University Hospital, I meet people with this neuromuscular disease at our 
outpatients’ clinic. They often ask whether physical activity and exercise are of any use. 
This question was actually the starting point for the work presented in this thesis, 
because when I turned to the literature for guidance, I could not find any answers! 
There were few studies of the effects of physical activity and exercise on myotonic 
dystrophy. Further, at that time, studies giving an overall picture of the effect of the 
disease on individuals were few and far between. 
1.2 MYOTONIC DYSTROPHY TYPE 1 (DM1) 
Neuromuscular diseases encompass many disorders caused by disturbances at any part 
of the motor unit and can, depending on pathology, broadly be divided into 
neuropathies and myopathies. One subgroup in the myopathies consists of muscular 
dystrophies, which form a group of inherited disorders characterised by muscle wasting 
and weakness 1. Included in this group are the myotonic dystrophies which are 
currently presented as two different clinical and genetic types, i.e. myotonic dystrophy 
type 1 which is most common, and myotonic dystrophy type 2, also known as proximal 
myotonic myopathy 2. 
Myotonic dystrophy type 1 (DM1) is a slowly progressive disease first described as a 
separate disorder in 1909 3-4. Characteristic symptoms are myotonia (a delayed 
relaxation after muscle contraction), and muscle weakness and wasting in neck and 
facial muscles, and in a distal-to-proximal progression order in the limb muscles. Other 
organs and systems can also be affected, such as the ocular, cardiovascular, respiratory, 
digestive, metabolic and endocrine systems, and the central nervous system (CNS); and 
DM1 is therefore recognised as a multi-system disorder 5-6. It is one of the most 
common neuromuscular diseases, with an estimated worldwide prevalence of 5-20 per 
100 000 7. However, the prevalence figures vary widely according to geography, e.g. 
0.5/100 000 in Taiwan 8, 10-18/100 000 in various European regions 9-11, 37/100 000 in 
Norrbotten, northern Sweden 12 and 189/100 000 in the Saguenay-Lac-Saint-Jean 
region in Quebec, Canada 13. Life expectancy is reduced in persons with DM1, 
especially in those who have early onset of the disease. Mean age at death is reportedly 
45 years for those with childhood onset and approximately 55 years for those with adult 
onset 14-15. The most common causes of mortality are respiratory and cardiac  
problems 14-15.  
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The mutation causing DM1 is an unstable expansion of a cytosine-thymine-guanine 
(CTG) trinucleotide repeat in the 3´-untranslated region of the myotonic dystrophy 
protein kinase (DMPK) gene in chromosome 19q 16-17. Different models have been 
proposed to explain how and why an expanded CTG repeat in a non-coding region of a 
gene can cause DM1, and evidence is accumulating that DM1 is an RNA-mediated 
disease 18-19.  
The number of CTG repeats in healthy individuals can vary from five to 37, and people 
with repeat sizes between 38 and 49 are said to carry the pre-mutation. They are 
unlikely to have symptoms, but there is an increased risk that their offspring will inherit 
larger repeat sizes and thereby the disease 20-22. The number of CTG repeats in persons 
affected with DM1 varies from 50 to several thousand 17, 21-22. Mutations in these 
regions are highly unstable and biased toward further expansions, which can explain 
the phenomenon of anticipation, i.e. the occurrence of increasing disease severity and 
decreasing age onset in successive generations, seen in DM1 17, 22-23. In addition to the 
genetic instability over successive generations, the CTG repeat is also somatically 
unstable within and between body tissues and with an age-dependent expansion process 
22, 24-27. The diagnosis is nowadays based on genetic testing with PCR analysis to detect 
CTG repeat sizes up to approximately 100 repeats and TP-PCR and/or Southern blot 
analyses to detect larger expansions 21, 28. There is a rough correlation between CTG 
expansion size and disease severity and age at onset, in that individuals with larger 
expansions have earlier onset and more severe symptoms 23, 29-30. At the same time, the 
prognosis for an individual in terms of age at onset, kind of symptoms and their 
severity, or rate of progression, cannot be made on the basis of the measured CTG 
expansion size 21, 24. 
The inheritance pattern is autosomal dominant, meaning that one copy of the mutated 
gene is sufficient to cause the disease and that it is passed on to both sexes with equal 
frequency. There is, however, a sex-specific inheritance difference. Women 
transmitting DM1 have a significant risk of having a severely affected child, while this 
is rarely seen when the affected parent is the father 22.  
DM1 can be subdivided into four forms based on the clinical presentation, i.e. age at 
onset and symptoms, and CTG repeat size: 1) the congenital form, 2) the childhood 
form, 3) the classic adult form, and 4) the mild adult form 2, 30-32. Congenital DM1 is the 
most severe form and symptoms are present in utero (lack of foetal movements, and 
polyhydramnios) or from birth (hypotonia, contractures of large joints, breathing and 
feeding difficulties, mental retardation) 32. The childhood form is without neonatal 
symptoms and development is normal within the first year. Age onset is before 10 years 
and reported symptoms include abdominal and mild motor problems, indistinct speech, 
variable degree of mental retardation, behavioural problems with learning disability and 
difficulties in relationships 32-33. Autism spectrum conditions and anxiety disorders are 
also associated with both the congenital and the childhood form of DM1 34-35. With 
time, people with the childhood form also develop the same symptoms as in the classic 
adult-onset form. In this form clinical signs such as myotonia and muscle weakness, 
and/or symptoms from the ocular, cardiovascular, respiratory, digestive, metabolic, 
endocrine, and the central nervous system, generally appear between the ages of 10 and 
30 years. This is in contrast to the mild adult form where onset is at older age (>40 
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years) and symptoms are few; only cataract and/or mild myotonia 36. There is however 
no absolute distinction between the different forms which, rather, form a continuum 37. 
The present work encompasses adults (defined as a person ≥ 18 years of age) with 
either the childhood form, the classic adult form or the mild adult form.  
1.3 ICF 
The International Classification of Functioning, Disability and Health (ICF) was 
developed by the World Health Organization (WHO) as a conceptual framework and a 
classification system providing a unified and standardized language to describe 
people’s health and health-related states from the perspective of body, individual and 
society 38. The ICF is a “components-of-health classification” and supplements the 
International Statistical Classification of Diseases and Related Health Problems (ICD-
10) 39, which provides an etiological framework and a “diagnosis” of diseases or 
disorders. By classifying functioning and disability associated with health conditions, 
i.e. diseases or disorders, a broader and more meaningful picture is given of 
individuals’ and populations’ experience of health 40. 
The ICF comprises two parts, see Figure 1. Part 1, Functioning and disability, includes 
the components body functions and body structures, and activities and participation. 
Part 2, Contextual factors, includes the components environmental factors and personal 
factors. Functioning is an umbrella term indicating non-problematic or neutral aspects 
of health, comprising all body functions, activities and participations. Disability, on the 
other hand, is used to indicate problems and summarizes body-function and body-
structure impairments, activity limitations and participation restrictions.  
Personal  
factors
Environmental 
factors
Activities and 
participation
Body functions 
and structures
Contextual factorsFunctioning and disability
ICF
 
Figure 1. Parts and components of the ICF. 
In the ICF, body functions relate to physiological and psychological functions of body 
systems, and body structures to anatomical parts of the body. Activity is defined as a 
person’s execution of a task or action, and participation as a person’s involvement in a 
life situation. Environmental factors refer to the physical, social and attitudinal 
environment in which a person lives and conduct his/her life. Personal factors are the 
individual background of a person’s life and living.  
The ICF is based on a “bio-psychosocial” approach, which is an integration of two 
different conceptual models of disability, i.e. the medical model and the social model. 
In the medical model, disability is seen as a feature of the person caused by disease, 
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trauma or other health conditions. Disability in the social model is viewed as a socially-
created problem and not at all an attribute of an individual. By synthesising these 
models, the ICF attempts to give a coherent view of different aspects of health. 
Functioning or disability is always an interaction between contextual factors, i.e. 
features of the person and of the overall context in which the person lives, and the 
health condition. Figure 2 represents the ICF model and illustrates the multiple 
interactions among the components. 
 
Figure 2. The ICF model: interactions between the components of the ICF. 
Except for personal factors, all the components can be classified and coded. An ICF 
component consists of domains, which incorporate categories, the units of the 
classification. The domains are arranged hierarchically (chapter, second, third and 
fourth level), which is reflected in the coding. The ICF categories are designated by a 
letter; b for body function, s for body structure, d for activity and participation (or a for 
activity; p for participation), and e for environmental factor. These are followed by a 
number where the first digit indicates the chapter, the next digit the second level and so 
on. See example below.  
 
Table 1. Organization and structure of the ICF coding. 
Level Example Coding 
Component Body functions b 
 Domain (chapter)  sensory functions and pain b2 
  second level   sensation of pain b280 
   third level    pain in body part b2801 
    fourth level     pain in back b28013 
Component Activities and participation d 
 Domain (chapter)  mobility d4 
  second level   walking d450 
   third level    walking long distances d4502 
Body function & 
structure (impairment)
Activities 
(limitation)
Participation 
(restriction)
Health condition 
(disorder/disease)
Personal factorsEnvironmental factors
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By adding qualifiers, numeric codes that specify the extent or magnitude of functioning 
or disability in that category or how far an environmental factor is a facilitator or 
barrier, an individual’s health and health-related state can be described. A generic scale 
is used to indicate a problem which may mean an impairment, limitation or restriction; 
0 = no problem, 1 = mild problem, 2 = moderate problem, 3 = severe problem, 4 = 
complete problem. Environmental factors are quantified either as barriers or facilitators 
using a 0-4 scale, where the sign + is used to denote facilitator, ranging from no to 
complete barrier/facilitator.  
The ICF model and classification are proposed for use both in clinical practice and in 
research 38, 40-44. In the clinic, the ICF can be applied as a tool for patient assessment, 
goal-setting, intervention management, and evaluation 41, 43-44. In research, it can 
provide a framework or structure, and a standard taxonomy for functioning, disability 
and health, thereby contributing in both research planning and reporting 42.  
However, a problem when using the ICF is the size of the classification system – over 
1400 categories. The ICF checklist 45 and several ICF core sets 46-47 have therefore been 
developed. The checklist 45 consists of 123 second-level categories, and a Swedish 
version is available from the National Board of Health and Welfare 48. Core sets are 
short lists of domains considered relevant for describing health conditions, and can be 
generic 47, condition-specific 46, 49-50 or developed for different settings 51-52. A 
searchable online version of the ICF, (http://apps.who.int/classifications/icfbrowser/), is 
provided by the WHO to facilitate the use of the classification. 
The ICF has been criticized as being too complex for daily use 53; that it lacks the 
subjective dimension 54-55; and is ambiguous concerning the differentiation of activity 
and participation 56-57. Pointed out is also the need for a classification of the personal 
factors 57 and that the ICF model should be expanded to include the concepts quality of 
life and human development 58.The conceptual platform of the ICF and the view of 
health expressed in the ICF have also been questioned by Nordenfelt 59-60. He argues 
that the distinction between activities and participation is not coherent, that the ICF 
lacks the concept of will, and that an opportunity qualifier would be more relevant than 
the ICF performance qualifier. 
In the present work, the ICF was used as a conceptual framework and taxonomy to 
explore functioning, disability and health, and the effects of a physical exercise 
programme, in adults with DM1. 
1.4 FUNCTIONING AND DISABILITY IN DM1 
Below are presented some aspects of functioning and disability in DM1 that, based on 
current research and clinical experience, are considered to be relevant. The vocabulary 
of the ICF is used in the headings and corresponds to the list of chapters, and the order 
in which they are presented, of the components body functions, and activities and 
participation. 
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1.4.1 Body functions  
1.4.1.1 Mental functions 
Excessive daytime sleepiness or hypersomnia is a prominent symptom of DM1. It 
occurs both in the childhood form 32, 61 and in the adult forms 62-64. The reported 
prevalence ranges from 20% to 52% 32, 61-65. Fatigue can be defined as “an 
overwhelming sense of tiredness, lack of energy, and feeling of exhaustion” that should 
be distinguished both from symptoms of depression and from muscle weakness 66. 
Fatigue is a problem in DM1, present in over 60% in both the childhood- and the adult-
onset forms 32, 61, 63, 67. The causes of excessive daytime sleepiness and/or fatigue are 
not fully understood. It seems likely, however, that they include hypoventilation, 
central and obstructive sleep apnoea, hypercapnia, direct central mechanisms and other 
pathophysiological mechanisms 65, 68-70. Psychostimulants, i.e. drugs that increase 
alertness, are used to treat excessive daytime sleepiness, although there is limited 
evidence to support their routine use 71. 
Cognitive function is remarkably varied among the DM1 population, ranging from 
normal function to severe mental retardation, the latter being associated with the 
congenital form. In the childhood form, mental retardation has been classified as 
borderline/mild to moderate 32, 37, 72. Persons with the adult form usually perform within 
the normal range on tests, although often lower than controls/normative data 33, 73-74. 
The cognitive profile is, however, uneven and problems are reported in executive 
functions, visuospatial and visuouconstructive functions, memory and attention 34, 73-77. 
There is a tendency to progression with age 75-76. Personality disorders associated with 
apathy and social avoidance 33, 78-79, and reduced ability to recognise facial emotions 80, 
are also present. 
The occurrence of depression and anxiety is somewhat unclear. The reported 
prevalence of depression in DM1 ranges from 2.5% to 32% 64, 81-82, and of anxiety 
disorders from 8% to 40% 81, 83. These discrepancies might be due to different 
assessment methods and criteria for classification of depression and anxiety disorders. 
Depression is not a significant problem according to some studies 64, 81, whereas others 
report that mild-to-moderate depression is more common in adults with DM1 than in 
controls 82, 84. An increased frequency of anxiety disorders is reported in the childhood 
form 32, 34, 83, but does not seem to be a prominent feature in the adult forms 85.  
1.4.1.2 Sensory functions and pain 
Visual impairment in adults with DM1 is often due to cataract, and can be the only 
symptom in the mild form 5. A higher prevalence of visual impairments, such as low 
visual acuity, hyperopia and astigmatism, was found in children with congenital and 
childhood DM1 than in controls 86. 
Pain is a common and frequent problem for persons with neuromuscular disease 87-91. 
Approximately 60-70% of studied adults with DM1 have reported pain, mainly of 
moderate intensity and with back and legs as the most frequent sites 88-91. Another 
frequent complaint is abdominal pain, reported by both children and adults 32, 92. 
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1.4.1.3 Voice and speech functions 
Speech problems in DM1 are mainly due to muscle weakness and myotonia 5, 93. A 
nasal and indistinct speech, with poor articulation, is often present in the childhood 
form 32. 
1.4.1.4 Functions of the cardiovascular and respiratory systems  
Impaired heart functions are frequent in DM1 and are progressive over time 94-95. Most 
common are conduction system abnormalities and arrhythmias, and less often 
ventricular and myocardial dysfunctions 95. The reported prevalence of abnormal 
electrocardiogram (ECG) recordings varies between 26% and 65% 94, 96-97. Clinical 
symptoms are, however, often absent, and regular cardiac investigations are therefore 
recommended 95, 98. It is recognized that persons with DM1 risk arrhythmia and sudden 
death 99-100, even children and adolescents with no other symptoms 101-102. Holter 
monitoring, i.e. 24-48-hour ambulatory ECG monitoring, should also be performed in 
addition to the annual conventional ECG, since many with a normal resting ECG show 
abnormalities on the Holter monitoring 95, 103.  
Persons with DM1 often have hypotension. A marked reduction in both systolic and 
diastolic blood pressure, even in persons classified as minimally affected, and a reduced 
age-related rise in blood-pressure, have been reported 5, 104. 
Respiratory impairments are common and are due mainly to ventilatory muscle 
weakness, even though myotonia of these muscles, and mechanical changes in chest 
wall and pulmonary compliance, also contribute 105-107. Pulmonary function tests reveal 
reductions in total lung capacity, vital capacity, forced vital capacity and in forced 
expiratory volume 69, 94, 105, 108. Mild-to-moderate restrictive lung disease was reported 
in 44% and severe in 14% of 57 persons with DM1 108. 
1.4.1.5 Functions of the digestive, metabolic and endocrine systems 
Gastrointestinal symptoms are common, and there are multiple reasons for these, 
including impairments of the nervous and neuroendocrine systems, and smooth and 
striated muscle weakness 109-111 Chewing and swallowing problems, caused by muscle 
weakness and myotonia 111-113 are frequent, and 30-55% reportedly perceive difficulties 
92, 111. Other common symptoms from upper and lower digestive tracts are heartburn, 
dyspepsia, nausea, vomiting, regurgitation, abdominal pain, bloating, constipation and 
diarrhoea 109-111. Anal incontinence can also be present both in children and in adults 109, 
111. A high incidence of gallstones has been stated to be a feature of DM1, although 
there is limited data to support this 5. 
Metabolic disturbances seen in DM1 include hyperinsulinaemia, insulin resistance and 
abnormal blood-lipid levels with high levels of triglycerides 114-115. Increased body fat 
mass and increased leptin levels are also present 114-116. Even though few studies 
document incidence or prevalence rates of diabetes mellitus in the DM1 population, a 
slightly increased incidence is reported 5. 
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Endocrine disturbances are widespread in DM1, involving several endocrine systems, 
and often with a sex discrepancy, males being more severely affected 115. Primary 
hypogonadism in males can give symptoms such as small testis with decreased sperm 
production, weak secondary sex characteristics, and breast enlargement 5, 115. 
Disturbances at several levels of the hyopothalamopituitary-adrenal system, with 
abnormal regulation of cortisol and androgens, disturbed secretion of growth hormone, 
and increased levels of cytokines, are reported 114-115.  
1.4.1.6 Genitourinary and reproductive functions 
Reduced fertility can occur in both sexes 5. Pregnancy complications are not 
uncommon and many are a direct consequence of uterine muscle involvement 117. 
1.4.1.7 Neuromusculoskeletal and movement-related functions 
Myotonia, which is a delayed relaxation after a muscle contraction, is often the first 
symptom of DM1 in adults 118-119. It is common in the hand muscles, making it difficult 
to release following a forceful grip. Myotonia is frequently described as a feeling of 
stiffness, and is aggravated by cold weather and diminished by repeated contractions, 
the warm-up phenomenon 5, 120. Other areas where myotonia occurs are jaw and tongue 
muscles 5, and respiratory muscles such as the diaphragm 106. Myotonia is reportedly 
most marked in persons with minor muscle weakness and a problem of less extent 5, 119. 
Different drugs, mostly sodium channel blockers, have been used to treat myotonia, 
even though a systematic review concludes that there is not enough evidence to 
determine whether any drug treatment of myotonia is safe and effective 121. 
Muscle weakness and wasting are the main features of DM1. Typical is the weakness 
of facial and jaw muscles and anterior neck muscles, and the distal-to-proximal 
progression of upper- and lower-limb muscle weakness 5, 119, 122. The facial weakness 
and wasting contributes to the typical facial characteristics of DM1 with ptosis 
(drooping eyelid), hollowing of the temples and a jaw that might hang open. Palate and 
pharyngeal muscle weakness is also common and can cause considerable problems, for 
example with swallowing and speech. Although distal weakness in hand and foot 
muscles is an early and prominent symptom, proximal muscles are also affected both in 
children and in adults with DM1 108, 123-124. The isometric strength in distal and 
proximal muscles is reduced compared to normative reference values or the strength of 
controls 108, 123, 125. Longitudinal studies confirm the progression of muscle weakness 
124-126. However, there is a considerable individual variation in both muscle weakness 
118, 123, 127 and rate of progression 118-119. 
The gait pattern is typical, due to foot drop; and was in a gait analysis study of five 
persons with DM1 described as a “foot-slap” pattern with reduced toe-off 
plantarflexion and abnormal hip motion 128. 
1.4.1.8 Functions of the skin and related structures 
Premature balding, with hair loss that may be both frontal and temporal, is common 
and is seen mainly in men with DM1 5. 
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1.4.2 Activities and participation 
1.4.2.1 Learning and applying knowledge 
Learning difficulties are a prominent symptom in the childhood form 32, 34, 37, 72, often 
being the cause of the first medical consultation; and many children with DM1 require 
special education 32.  
1.4.2.2 General tasks and demands 
Although not exclusively studied, people with DM1 may have difficulties with general 
tasks, for example when undertaking multiple tasks, carrying out daily routines, and 
handling stress and other psychological demands. 
1.4.2.3 Communication 
Communication difficulties are common in children and adolescents with DM1 35, 72, 
129. The dysarthric speech seen in adults can also lead to communication difficulties 119. 
1.4.2.4 Mobility 
Limitations in mobility are common in DM1 and increase over time 94, 130-133. Walking 
and balance difficulties, and a high risk of falls, have been shown in adults 134-135. 
1.4.2.5 Self-care 
Both children and adults can have limitations in activities related to self-care, although 
most adults seem to be independent in personal activities of daily living (ADL) 72, 129-
130, 133. Longitudinal studies show that the dependency in ADL increase with time 133, 
136. 
1.4.2.6 Domestic life 
Examples of areas included in the ICF domain domestic life are; “acquiring a place to 
live, food, clothing and other necessities; household cleaning and repairing; caring for 
personal and other household objects; and assisting others” 38. Activity limitations and 
participation restrictions in areas of domestic life are reported mainly in adults 130-131, 
133, 136, but can also be present in children with DM1 72.  
1.4.2.7 Interpersonal interactions and relationships 
It is commonly reported that children with DM1 have social difficulties 32, 34-35, 72, 79. A 
deterioration in social interaction, which increases over time, has also been shown in 
adults 94, 133, 136. 
1.4.2.8 Major life areas 
Participation restrictions concerning work and employment seem common in DM1 130-
131, 137-138. Persons with DM1 are reported to have lower education levels, reduced 
employment rates, lower family income and higher reliance on social assistance, 
compared to a general reference population 138.  
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1.4.2.9 Community, social and civic life 
Activity limitations and participation restrictions in community, social and civil life, are 
not uncommon. Adults report difficulties concerning recreation and leisure 130, 133, 136, 
and there is deterioration over time 133, 136. Notable shortcomings in community areas 
are reported in children with DM1 and few attend leisure-time activities 72.  
1.5 CONTEXTUAL FACTORS IN DM1 
Disability, as the term is used in the ICF, denotes the phenomenon resulting from the 
interaction between a person and his/her physical and social environment 38. This 
implies the importance of contextual factors, and they should also be covered to 
provide a complete picture of the effect of a disease. What follows summarizes aspects 
of environmental and personal factors in DM1. 
1.5.1 Environmental factors 
Environmental factors can be thought of as either barriers to or facilitators of 
functioning 38. Although the literature is scarce on how persons with DM1 perceive 
environmental factors, the following ICF environmental factor domains can act as 
facilitators: products and technology; support and relationships; attitudes; and services, 
systems and policies. Examples of these are drugs for alleviating impairments such as 
excessive daytime sleepiness and fatigue; pain; cardiovascular, gastrointestinal and 
endocrine problems; and myotonia 5. Further examples are assistive devices such as 
orthotic, mobility, ADL and technological aids; home adaptations; and public services, 
which all aim to enhance activity and participation. Negative support and attitudes from 
family and friends, obstacles related to access and use of technology and to government 
and public services, were in a study of 200 persons with adult onset found to form 
barriers which were identified as predictors of participation limitations in domestic life, 
mobility, employment and recreation 139. 
1.5.2 Personal factors 
Personal factors are attributes of the individual such as age, gender, social background, 
education, life experience and coping styles. They are important to survey as they may 
affect the outcome of interventions. Low education level is a common factor that partly 
explains disrupted participation in domestic life, mobility, employment, and recreation 
in adults with DM1 139. Further, persons who were married/common-law partners were 
less likely to be social-assistance recipients, and men were more likely than women to 
have low support from family 138. Age, gender and educational levels were predictors 
of employment status in DM1. Most likely to be employed were younger men with 
higher education levels 140. Coping has been evaluated in persons with various 
neuromuscular diseases, including DM1 131, 133, 141. Emotion-focused coping, i.e. ways 
in which a person handles emotions associated with stressful situations, is reportedly 
used more often than problem-focused coping, i.e. dealing with the problem itself 141. 
Further, coping strategies remain stable over time 133.  
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1.6 HEALTH-RELATED QUALITY OF LIFE 
1.6.1 General aspects 
Although it is possible to give a comprehensive view of a person’s health using the 
WHO classifications, no description of health status is complete without reference to 
quality of life (QoL). The term is ill-defined according to Fayers and Machin 142, and 
the concept depends on the theoretical perspective and the context in which it is used. 
QoL can be thought of as a construct of well-being. In the ICF, well-being is defined as 
a general term that includes all human life areas – physical, mental and social aspects – 
that make up a “good life” 38.  
Health has been defined by the WHO as “a state of complete physical, mental and 
social well-being, and not merely the absence of disease or infirmity. Health is a 
resource for everyday life, not the object of living. It is a positive concept emphasizing 
social and personal resources as well as physical capabilities” 143. This implies that 
health is multidimensional and points to the complexity of the concept. Health is a 
personal experience and can therefore only be rated by the person him- or herself. Self-
rated health is an overall assessment of a person’s perception of his/her general health 
status and is a predictor of clinical outcome and mortality 144. The difference between 
QoL and health is not clearly defined in the literature. It is generally agreed that QoL is 
a multidimensional construct and includes components of happiness and satisfaction 
with life 142. The term health-related quality of life (HRQoL) is a pragmatic 
delimitation from QoL in its more general sense, and is concerned mainly with 
functioning and well-being in relation to illness and treatment 145. HRQoL refers 
perhaps to aspects of QoL that may be affected by health status and health care. There 
is no universal agreement on what dimensions of QoL should be included in HRQoL, 
and the concept may therefore vary between studies. In general, HRQoL questionnaires 
reflect the multidimensional construct, and include at least items focusing upon general 
health, and physical, emotional and social functioning 142. 
1.6.2 Health-related quality of life in DM1 
Reduced HRQoL in physical functioning 133, 136, 146 and in psychosocial functioning, 
and deterioration over time 133, 136 have been shown in adults with DM1. Overall 
HRQoL is also significantly lower than in healthy controls and the general population 
84.  
1.7 HEALTH CARE AND REHABILITATION IN DM1 
As there is no curative therapy for DM1, management of the disease symptoms is 
essential to overall well-being. The complexity and the variability of DM1 call for a 
coordinated multidisciplinary team approach for achievement of optimal outcomes 98, 
147-148. The overall aims are to relieve impairments, reduce limitations and optimise 
participation. There are no national Swedish guidelines or standards for provision of 
specialist care. There is, however, a Scandinavian consensus programme 98 with 
recommendations on health care including habilitation/rehabilitation. Regular yearly 
structured follow-ups and collaboration between specialists are advocated 98. The 
availability of specialist care usually depends on where you live. Hill and Philips 
describe specialist care for persons with neuromuscular disease in the United Kingdom 
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as concentrated in areas of high population density 149. They also point out that most 
neuromuscular disease clinics are not a result of local or national planning, but rather 
due to clinicians with a special interest. The same probably applies in Sweden. To 
improve health care for people with DM1, nursing case management on a disease-
management model has recently been proposed 150. The model’s components include 
“population identification processes, evidence-based practice guidelines, collaborative 
practice, patient self-management education, and process outcome evaluation”. 
Few multidisciplinary rehabilitation programmes have been scientifically evaluated and 
there is therefore limited data to support this form of rehabilitation for people with 
DM1. A rehabilitation programme in a hospital setting showed some positive effects on 
balance in gait in 20 adults with DM1 151. In the county of Örebro, Sweden, adults with 
muscular dystrophy are offered a comprehensive rehabilitation programme that is 
tailored to their medical, physical and psychosocial needs. The effects on ADL, coping 
and QoL of this programme were assessed in a quasi-experimental controlled clinical 
study 152. Although no significant effects were shown, the results indicate that the 
participants reduced maladaptive coping patterns 152. Physiotherapy was included in the 
programme, and physiotherapists are commonly involved in both the evaluation and 
management of persons with DM1. 
1.8 PHYSIOTHERAPY 
1.8.1 General aspects 
Hislop proposed a model of pathokinesiology, the science of abnormal human 
movement, as the basis for physiotherapy 153. A hierarchical pattern at six different 
levels of the human organism; cell, tissues, organs, systems, persons and family, was 
used to define the science of physiotherapy and its application. Physiotherapy was 
described as a profession that uses therapeutic exercises to prevent, evaluate, and treat 
disorders of human motion 153. In Sweden, this model has been further developed as a 
model of human movement by Tyni-Lenné 154, who describes the movement hierarchy 
as expressing three aspects ; movement prerequisites, movement capacity and 
movement behaviour; and how they interact. Tyni-Lenné has also presented a problem-
solving model, the “physiotherapy process” 155, which describes the clinical reasoning 
and decision-making process on which physiotherapy interventions are based. 
Building on Hislop’s pathokinesiology model, the movement continuum theory of 
physical therapy 156 was published in 1995 and presented as a grand theory of 
physiotherapy. Movement is the key concept here and is conceptualised as a continuum 
from micro (molecular) level to macro (person in society) level influenced by external 
and internal factors. Every person is said to have a maximum, current and preferred 
capability to move at each level of the movement continuum determined by biological, 
psychological and social factors 156. The aim of physiotherapy practice is to maintain, 
improve or prevent deterioration of current movement capability with interventions 
directed at minimising the difference or gap between preferred and current movement 
capability 156. An extension of the movement continuum theory has been proposed by 
Allen 157. A model subdividing movement into six dimensions, i.e. flexibility, strength, 
accuracy, speed, adaptability and endurance, and a self-report measure with focus on 
movement, are described 157-158. Although the model has been questioned 159, the 
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measure provides evidence supporting the theoretical construct of the preferred and 
current movement capability gap described by the movement continuum theory 160. 
Physiotherapy is currently defined by the World Confederation for Physical Therapy 
(WCPT) in a position statement from 2007 161 as services to persons to “develop, 
maintain and restore maximum movement and functional ability throughout the 
lifespan” when “threatened by ageing, injury, disease or environmental factors” 161. 
Movement is considered an essential element of health and well-being. Physiotherapy 
is “concerned with identifying and maximising quality of life and movement potential 
within the spheres of promotion, prevention, treatment/intervention, habilitation and 
rehabilitation. This encompasses physical, psychological, emotional, and social well-
being” 161. An integral part of physiotherapy is the interaction process between the 
physiotherapist and the patient/client, his/her family, and others. Included in this 
process are both the assessment of movement potential and the agreement upon goals. 
At the request of the Swedish Association of Registered Physiotherapists, the WCPT 
document was further developed for Swedish conditions. “Physiotherapy as science and 
profession” by Broberg and Tyni-Lenné 162 gives a comprehensive view of the 
historical development, the fields of knowledge, the core concepts, the professional 
autonomy, the physiotherapy process, and areas and fields of application within 
physiotherapy. Both the movement continuum theory 156 and the ICF framework 38 are 
integrated in this definition of physiotherapy 162.  
1.8.2 Physiotherapy in DM1 
The literature describing physiotherapy in DM1 is scarce. Nitz 163 advocates a holistic 
approach to management and asserts that understanding all the patient’s problems is 
important for compliance with treatment. Suggested interventions include respiratory 
physiotherapy, exercise programmes, and the prescription of mobility aids and orthoses 
163. The aims of physiotherapy in neuromuscular diseases in general are to prevent 
complications, and to maintain and/or improve functioning and quality of life 164-165. 
Regular contact with physiotherapists is emphasised for persons with DM1 in the 
Scandinavian consensus programme 98. Regular adapted physical activity is also 
recommended 98. In summary, depending on the level of function and disability, 
physiotherapy for persons with DM1 varies and may consist of individual training and 
treatment, prescription of orthoses and mobility aids, and of advice on, and the 
prescription of, physical activity and exercise 98, 163-166. 
1.9 PHYSICAL ACTIVITY AND EXERCISE 
1.9.1 General aspects 
Physical activity is defined as “any bodily movements produced by skeletal muscles 
that result in energy expenditure” 167. Accordingly, physical activity encompasses 
almost everything a person does during his/her waking hours, and can in daily life be 
categorised into occupational, sports, conditioning, household, and other activities. 
Exercise, on the other hand, is “a subset of physical activity that is planned, structured, 
and repetitive” with the purpose of improving or maintain physical fitness 167. Whereas 
physical activity is related to the movements performed, physical fitness is health- or 
skill-related attributes that a person has or achieves. Cardiorespiratory endurance, 
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muscular endurance, muscular strength, body composition and flexibility are the five 
health-related components of physical fitness 167. 
Physical activity is an important factor for general health. Physically active people have 
higher health-related fitness, lower risk of developing medical conditions, and lower 
rates of chronic diseases, than the physically inactive 168. Regular physical activity in 
adults and older adults (men and women age ≥ 65 years), lowers the rate of all-cause 
mortality, and reduces the risk of coronary heart disease, cardiovascular disease, stroke, 
hypertension, type 2 diabetes, metabolic syndrome, colon cancer, breast cancer and 
depression 168. Further, being physically active is associated with better-quality sleep 
and health-related quality of life, and, in older adults, with a reduced risk of falling and 
with better cognitive function 168. Evidence is also accumulating for the prescription of 
physical activity in the treatment of a number of chronic diseases such as metabolic 
syndrome-related disorders; heart and pulmonary diseases; muscle, bone and joint 
diseases; cancer; and depression 169-171. 
The recommendation of the physical activity needed to promote and maintain health 
among healthy adults is: moderately intense aerobic physical activity for a minimum of 
30 minutes a day, five days a week, or vigorously intense aerobic physical activity for a 
minimum of 20 minutes a day, three days a week; and eight to 10 strength-training 
exercises, each repeated eight to 12 times, twice a week 172. It is possible to combine 
moderately and vigorously intense physical activity to meet the recommendation 172. 
The guidelines for older adults and adults with chronic conditions are basically the 
same as for healthy adults, although emphasis is put on moderately intense aerobic 
activity, strength-training exercises, flexibility and balance exercises, reducing 
sedentary behaviour, and the development of an activity plan 173. 
1.9.2 Physical activity and exercise in DM1 
People with progressive neuromuscular diseases, such as DM1, are less active than 
healthy people 134, 174-176. The reduced physical activity can be due to the disease itself 
or to a sedentary lifestyle 177, and there is a risk of secondary chronic conditions such as 
cardiovascular diseases and diabetes 174-175, 177. The role of physical activity and 
exercise has not been extensively studied in DM1. Recent reviews conclude that 
existing studies are limited both in regard to number and quality 178-182. Exercise 
programmes, in which at least five people with DM1 have participated, consist of 
resistance training 183-188, aerobic training 189-190 and qigong 191-192. The programmes 
have been home-based 183-185, 189-190, individually supervised 186 or a combination of 
home-based and supervised group training 187-188, 191-192.  
Major shortcomings of these studies are that they have included persons with various 
neuromuscular diseases 183-184, 189, 191-192, thus making it impossible to interpret the 
results for each separate disorder. Further, sample size is generally small, varying from 
five to 19 persons with DM1 183-184, 186-187, 189-192, although two studies 185, 188 included 
35 and 33 persons, respectively. Except for these two latter studies of strength training 
185, 188 and qigong 191-192, none have been randomised or controlled. Strength training 
has in several studies been performed in few muscles, e.g. in knee extensors, elbow 
flexors, and hand/finger extensors/flexors, 183-184, 186-187, and sometimes only on one side 
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of the body 183-184, 186. The description of the characteristics of participants with DM1 is 
generally limited, and information on whether the diagnosis is genetically verified is 
often lacking. Thus, it is difficult to assess to whom the findings can be generalized. 
Despite these limitations, authors of studies analysing persons with DM1 as a group 
conclude that the exercise regimes have been well tolerated 185-188, 190. Improvements in 
muscle strength 186, hand function 187-188 and aerobic capacity 190 are reported. The 
clinical relevance of these improvements is, however, uncertain and rarely discussed. 
From the only study with adequate quality, a randomised clinical trial of a 24-week, 
home-based, progressive resistance exercise programme in 33 DM1 patients 185, neither 
beneficial nor negative effects were shown. Although existing evidence is limited, 
persons with slowly progressive neuromuscular diseases are recommended low-to-
moderate-intensity strength and aerobic exercise training, as well as the adoption of an 
active lifestyle 179, 181, 193. However, no studies evaluate the effects of a more 
comprehensive training programme where strength, aerobics, flexibility, and balance 
exercises are included. 
When promoting physical activity and exercise for people with chronic conditions such 
as DM1, reference settings outside the health care system are important. 
Friskis&Svettis® is a Swedish non-profit sports association providing different forms 
of exercise. There are 113 local associations throughout the country and approximately 
5% of Sweden’s inhabitants are members 194. The aim is to provide engaging and easily 
accessible exercise of high quality for everyone. Friskis&Svettis® has – in cooperation 
with the Swedish Association of People with Mobility Impairments (DHR), the 
Swedish Association for Persons with Neurological Disabilities (NHR) and the 
Swedish Association for Survivors of Accident and Injury (RTP) – developed a special 
form of training programme for persons with disability called “Öppna dörrar” (Open 
Doors). This group exercise programme is supported with music, and comprises 
aerobic activities, muscular strength and endurance exercises, and balance and 
flexibility exercises. Open Doors classes are available at nine of the local associations. 
This form of exercise seemed to be appropriate for people with DM1, but before 
referring them to Open Doors classes, an evaluation of the feasibility and effects of the 
programme was needed. 
1.10 VALIDITY, RELIABILITY AND FEASIBILITY 
To evaluate the effects of an intervention, tests and measures are needed. They may be 
designed and used for different purposes; to discriminate, predict or evaluate 195. 
Evaluative tests and measures can measure changes over time in an individual or group, 
and are therefore often called outcome measures. When choosing outcome measures, it 
is important to consider both the measurement properties, i.e. validity and reliability, 
and the feasibility for the target population 195. 
Validity relates to the meaningfulness and usefulness of a test or measure, how far it 
assesses what it is supposed to measure. The main types of validity are face validity, 
content validity, construct validity, and criterion validity; although additional terms 
have been used in connection with construct validity 195. Validity is not an inherent 
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property of a test or measure, but rather a matter of degree 196: it is context-specific, and 
a test or measure is never just valid, it is valid for making certain measurements.  
Reliability has to do with the consistency, reproducibility and repeatability of a test or 
measure. It can be defined as the degree to which a test or measure is free from 
measurement error. The two main components of reliability are the ability to 
differentiate among patients/persons who are being tested or measured, and 
consistency, i.e. to provide consistent values with small measurement errors 195. 
Systematic and random errors are the main sources of variability associated with 
measurement error. Systematic errors are predictable, constant and biased, occurring in 
one direction only, such as learning or fatigue effects 197-198. Random errors are 
unpredictable and can be caused by inherent biological or mechanical variation, or by 
inconsistencies in the measurement procedures 198.  
Reliability also comes in different types: internal consistency, test-retest reliability, 
intra-rater and inter-rater reliability. Internal consistency is most often associated with 
questionnaires and relates to the homogeneity, i.e. how well items that reflect the same 
construct yield similar results 195. Test-retest reliability concerns the consistency of 
repeated measurements over time, when patients/persons are believed to be stable 
concerning the measured attribute. Intra-rater reliability refers to how far measures 
obtained by the same rater on different occasions will be consistent, and inter-rater 
reliability concerns the agreement between two or more raters. 
The reliability of a test or measure can be expressed as relative or absolute 195. Relative 
reliability refers to the ability to distinguish among patients/persons and when based on 
interval/ratio level data, is usually assessed with intra-class correlation (ICC) methods. 
Absolute reliability describes the degree to which repeated measurements vary for 
individuals and is expressed either in the actual units or as a proportion of the values 
measured 198. Common methods of assessing absolute reliability when based on 
interval/ratio level data, are calculation of the standard error of measurement (SEM), 
the repeatability coefficient, and coefficients of variation (CV%, SEM%, 
repeatability%) 199-201. Absolute reliability results can be used to determine limits for 
the smallest difference that indicates a real change in an individual or a group 199. 
Tests and measures should not only be reliable, but also show sensitivity to change and 
responsiveness. These are two important and closely-related, although different, 
measurement properties. Liang 202 has defined sensitivity to change as “the ability of an 
instrument to measure change in a state regardless of whether it is relevant or 
meaningful to the decision-maker. Sensitivity to change is a necessary but insufficient 
condition for responsiveness”. Responsiveness, on the other hand, is defined as “the 
ability of an instrument to measure a meaningful or clinically important change in a 
clinical state” 202. It is the patient/person, his/her proxy or the health professional who 
defines what a clinically meaningful or important change can be, and it is therefore 
evaluated from that individual’s perspective. According to Liang 202, the change should 
be noticeable, of value, and exceed variation attributable to chance. 
Feasibility is an important aspect when choosing outcome measures. Ideally, a test or 
measure is time-efficient, inexpensive, and easy to administer and score. The 
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respondent burden, i.e. the time and difficulty it imposes on the patient/person, must 
also be considered. Further, it should also be possible to interpret the data gathered into 
information that can be evaluated and used in the clinical and/or research setting. 
1.11 RATIONALE 
Assessment of human functioning, disability and health is a unique feature in physical 
and rehabilitation medicine – which includes physiotherapy – and is used to understand 
a person’s experience of disability, so that health services can be selected aiming at 
optimizing function 203. Some studies describe functioning and disability in DM1, but 
few give a comprehensive view of concurrent body-function impairments, activity 
limitations and participation restrictions in the same sample of adults with genetically 
confirmed DM1. It is therefore unknown how the individual is affected. Further, the 
influence of environmental factors has not been extensively explored. Thus, we lack an 
overall picture of the effect of the disease in a DM1 population.  
Tests and measures are used to gather information about patients/persons in 
rehabilitation and physiotherapy. If the effects of services in these fields are to be 
evaluated, outcome measures that are valid, reliable, and feasible are needed. Studies 
exploring these aspects in persons with DM1 are, however, scarce. Consequently, 
studies on the feasibility and reliability of outcome measures are required. 
In summary, physical activity and exercise are acknowledged as an important factor for 
general health 168. The scientific evidence supporting recommendations on physical 
activity and exercise in neuromuscular disease in general, and in DM1 in particular, is, 
however, limited due to lack of research. Accordingly, there is a need for studies that 
explore type and amount of physical activity and exercise programmes for persons with 
DM1. 
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2 AIMS 
2.1 GENERAL AIMS 
The overall aims of the work presented in this thesis were to explore aspects of 
functioning, disability and contextual factors in adults with DM1; to describe the 
reliability and feasibility of the six-minute-walk test, and to evaluate the feasibility and 
effects of a physical exercise programme. 
2.2 SPECIFIC AIMS 
The specific aims of the work were 
• to describe and analyse self-rated perceived functioning, disability and 
environmental facilitators/barriers with regard to different stages of the disease, 
i.e. disease severity, using the modified ICF checklist, in adults with DM1 
(Study I), 
• to describe and analyse functioning and the presence of concurrent body-
function impairments, activity limitations and participation restrictions with 
regard to different stages of disease progression, using data from tests and 
questionnaires, in adults with DM1; further to explore associations of measures 
of manual dexterity and of walking capacity with measures of activities and 
participation (Study II), 
• to describe the test-retest reliability and feasibility of the six-minute-walk test in 
adults with DM1; in particular to investigate possible learning effects of 
repeated tests, to describe relative and absolute reliability, to determine limits 
for the smallest differences that indicate a real change, and to describe 
feasibility (Study III), and 
• to investigate the feasibility and effects of a comprehensive group exercise 
training programme, the Friskis&Svettis® Open Doors, on functioning and 
health-related quality of life in adults with DM1 (Study IV). 
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3 METHODS 
3.1 DESIGN 
Studies I and II have a cross-sectional design, Study III a test-retest design, and Study 
IV a randomized controlled trial design. 
3.2 PARTICIPANTS 
To recruit as many persons with DM1 as possible in the Stockholm County Council 
area, all the major hospitals and private practitioners with neurological speciality were 
contacted and informed about the studies by mail (I, II). This resulted in a list of 128 
persons, mainly from the outpatient clinic at the Department of Neurology, Karolinska 
University Hospital, Stockholm, Sweden. The inclusion criteria were diagnosed DM1, 
18 years of age or older, and living in the Stockholm County Council area. Twenty-one 
of the 128 persons did not fulfil these (14 had other muscular dystrophies or myotonic 
disorders, five lived outside the area, one had died and one was under 18 years). Thus, 
107 persons were eligible for the studies and they were first contacted by mail and then 
by telephone. Of these 33 declined participation and four did not reply, so 70 persons 
with DM1 were included in Studies I and II.  
Study III consisted of a reliability and a feasibility part, with different participant 
recruitments. From the 107 eligible persons with DM1 in the first two studies, 12 were 
recruited to the reliability part. Inclusion criteria were: diagnosed DM1 and ability to 
walk at least 30 metres with or without walking aids and/or ankle-foot orthosis. The 
persons were all well known at the Department of Physical Therapy at Karolinska, and 
were selected to represent the different sexes, ages and stages of disease progression 
(muscular impairment). 
Data for the feasibility part of Study III were collected in connection with Studies I and 
II. Of the 70 persons in these studies, six were unable to walk, and thus 64 were 
included.  
In Study IV participants were recruited from the earlier-described 107 persons with 
DM1. However, three persons had died and 10 new cases had been identified, resulting 
in 114 eligible persons. Inclusion criteria were the same as in Studies I and II, plus: 
classified as grade 2-5 on the muscular impairment rating scale (MIRS) 204, ability to 
walk 50 m without assistance, and permission from a cardiologist to take part in an 
exercise programme. Exclusion criteria were clinically obvious, severe cognitive 
impairment, other diagnoses that could interfere with participation, and inability to 
understand and communicate in Swedish. Of 114 eligible persons with DM1, 35 did 
not fulfil the inclusion criteria (24 were unable to walk 50 metres, four had no muscular 
impairment, four had severe cardiac arrhythmia, two had other concurrent diagnoses 
and one did not speak Swedish). Seventy-nine persons were contacted first by mail and 
then by telephone. Of these, 41 declined participation and three did not reply. Thus, 35 
persons with DM1 were included in Study IV.  
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All participants had a genetically confirmed diagnosis, either in a first-degree family 
member (n=1) or in themselves (all other participants). They were classified by DM1 
form by their treating neurologist. See Figure 3 for participant recruitment.  
128
21 excluded
107
33 declined
4 no reply
3 died
35 excluded
41 declined
3 no reply
114
10 new cases
Studies I, II
70
Study III
64 feasibility
Study III
12 reliability
Study IV
35
6 excluded
 
Figure 3. Participant recruitment to the studies. 
 
3.3 PROCEDURES 
All data was collected at the Department of Physical Therapy, Karolinska University 
Hospital, Stockholm, Sweden.  
3.3.1 Studies I, II 
Data collection for the cross-sectional Studies I and II was divided over two occasions, 
A and B, in a random order. The order and instructions on each occasion were 
standardized according to a test protocol. Occasion A consisted of a standard 12-lead 
ECG recording, and tests of grip strength, lower-extremity performance, manual 
dexterity and walking, and mobility and ADL questionnaires. A structured interview 
was used to collect information on personal and environmental factors. Participants 
were also interviewed for self-rating of functioning/disability and environmental 
barriers and/or facilitators according to a modified version of the ICF checklist. 
Occasion B consisted of anthropometric measurements, spirometry, a sub-maximal 
cardiorespiratory fitness test, and questionnaires. The data presented in Study I was 
collected on occasion A with structured interviews. The data presented in Study II was 
collected on occasions A and B, with structured interviews, examinations, tests and 
questionnaires. Except for the ECG recordings and spirometry tests, which were 
conducted by an assistant nurse and an experienced biomedical analyst, respectively, all 
interviews, tests and questionnaire were administered and conducted by the present 
author (MK). 
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3.3.2 Study III 
In the reliability part of Study III, data was collected on two separate occasions, one 
week apart, administered by two undergraduate physiotherapy students supervised by 
the present author (MK). Information, instructions and procedures followed a study 
protocol. Each student administered the tests to the same participant on the two 
occasions, and the tests were performed at the same time of day. Data for the feasibility 
part of study III was collected on occasion A as described above.  
3.3.3 Study IV 
In Study IV, data was collected within three weeks before the start and within two 
weeks after the end of the exercise intervention by two independent experienced 
physiotherapists, blinded to group allocation and each assessing the same participants 
on both occasions. Information on and instructions for the tests were standardized 
according to a study protocol and the two physiotherapists were familiar with the tests. 
In addition to tests and measures, participants answered questionnaires. They gave 
information on personal and environmental factors in structured interviews. Participants 
in Study IV were stratified for level of functioning based on the six-minute-walk test 
(6MWT) 205. The median value of the 6MWT results from data collection before the 
start of the exercise intervention was used to divide the participants into two strata from 
which they were assigned by lot to either a training group or a control group. See 
Figure 4 for study design. The group training and the data collections were performed 
at different premises of the hospital (different buildings several blocks apart) and 
participants were informed not to reveal group affiliation at the evaluation after the 
exercise intervention. 
 
Figure 4. Design of Study IV. 
Assessed for eligibility n=114
Excluded n=79
did not meet inclusion criteria n=35 
declined n=41, no reply n=3
Data collection before randomisation n=35
Randomisation n=35
Training group n=18 Control group n=17
Data collection after intervention
Training group: n=18 
Control group: tests n=16, questionnaires n=17
Intervention
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3.4 MEASURES 
An overview of used measures in the present work is presented in Table 2. 
 
Table 2. Overview of measures used. 
 
Study 
I 
Study 
II 
Study 
III 
Study 
IV 
Modified ICF checklist ●    
Epworth sleepiness scale  ●  ● 
Fatigue severity scale  ●   
Hospital anxiety and depression scale  ●   
ECG recording  ●  ● 
Spirometry  ●   
Åstrand-Rhyming test   ●   
Grip strength test  ●   
Timed-stands test  ●  ● 
Nine-hole peg test  ●   
Timed up-and-go test    ● 
Six-minute-walk test  ● ● ● 
Rivermead mobility index  ●   
Katz Personal ADL index  ●   
Katz Instrumental ADL index  ●   
Frenchay activities index  ●   
Muscular impairment rating scale ● ● ● ● 
Anthropometric measures  ● ● ● 
Physical activity index  ●  ● 
Exercise self-efficacy scale    ● 
Short-form 36 health survey    ● 
Study-specific structured interviews on personal 
and environmental factors 
● ●  ● 
Study-specific questionnaires on perceived 
effects and experience 
   ● 
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The ICF checklist 
3.4.1.1 The modified ICF checklist (Study I) 
The ICF checklist 48 was modified by exclusion of all body-structure categories, by 
omitting 42 other categories from the original list and by adding 37 categories from the 
ICF classification, mainly from the activity and participation domain. This was because 
the checklist was to be used for self-assessment, and should capture information on 
functioning, disability and environmental factors thought to be relevant for persons 
with DM1, based on clinical experience and findings in the literature. The modified 
ICF checklist (see appendix) was used for self-rating of perceived problems in 29 body-
function categories, difficulties in 52 activity and participation categories, and barriers 
and/or facilitators in 23 environmental-factor categories with the following ICF 
qualifiers: 
0=no problem/difficulty/barrier 0= no facilitator 
1=mild problem/difficulty/barrier  +1=mild facilitator 
2=moderate problem/difficulty/barrier  +2=moderate facilitator 
3=severe problem/difficulty/barrier  +3=substantial facilitator 
4=complete problem/difficulty/barrier  +4=complete facilitator 
The qualifier scale above was transformed to a three-grade scale (0=no, 1=mild to 
moderate, 2= severe to complete) for descriptive presentation, and dichotomized (0=no 
problem/difficulty, 1= problem/difficulty) for analysis. 
Functioning and disability in activities and participation can be described as a person’s 
capacity and performance. The latter indicates what a person does in his or her current 
environment, with assistive devices if needed, and was used in the present self-rating of 
perceived difficulties. 
The ICF checklist is not a psychometric measure, but a classification. Nonetheless, an 
individual’s functioning and/or disability is classified using the qualifiers described 
above. The checklist may be supplemented with any information from written records, 
the primary respondent, other informants and direct observation 45. Here primary 
respondent information was used, as knowledge of persons’ own perceptions is of 
significant value and can assist in the development of health services. The construct 
validity of the ICF framework has been supported in a retrospective validation study 
using ICF core sets 206. Moderate responsiveness has been demonstrated for the ICF 
core set used with qualifiers on a modified three-point scale for patients with 
rheumatoid arthritis 207. Studies of the reliability of the qualifier measurement system 
have all shown low-to-moderate agreement 208-212. However, when the scale was 
reduced from five grades to three, reliability improved 210. So far, there seem to be no 
studies of validity or reliability of the ICF checklist, including the qualifiers, in persons 
with DM1. 
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3.4.2 Body functions 
3.4.2.1 The Epworth sleepiness scale (Studies II, IV) 
Excessive daytime sleepiness was evaluated with the Epworth sleepiness scale (ESS) 
213-215. The ESS eight items concern how likely the respondent is to fall asleep/doze off 
in different situations. Each item is rated on a scale from 0 to 3, and possible scores 
range from 0 to 24 with higher scores meaning more sleepiness. A score above 10 
(≥11) was used to indicate the presence of excessive daytime sleepiness 215 and was 
classified as a body-function impairment. The scale has a high degree of internal 
consistency, but there are insufficient data on validity and responsiveness 216. The ESS 
is stable over time in persons with DM1, and sufficiently reliable 217. It is recommended 
for use in DM1 218. 
3.4.2.2 The fatigue severity scale (Study II) 
Fatigue was evaluated with the fatigue severity scale (FSS) 219. This scale’s nine items, 
concern the effects of fatigue on daily functions, which are rated on a Likert scale 
ranging from 1 (strongly disagree) to 7 (completely agree). The mean of all item scores 
constitutes the FSS score, which has a possible range from 1 to 7. A higher score 
indicates a higher level of fatigue. A score equal to or over 4 (≥4) was used to indicate 
the presence of fatigue 219-220 and was classified as a body-function impairment. The 
scale is considered to be valid and reliable in various patient populations 220-222. It is 
stable over time in persons with DM1 and has high reliability 217. 
3.4.2.3 The hospital anxiety and depression scale (Study II) 
Anxiety and depression were evaluated with the Swedish version of the hospital 
anxiety and depression scale (HAD) 223-224. The scale’s two subscales evaluate the 
levels of anxiety and depression, respectively. Each subscale consists of seven 
questions with regard to the person’s feelings ‘last week’, and possible subscale scores 
range from 0 (no symptoms) to 21 (maximum distress). A score above 10 (≥11) was 
used to indicate anxiety disorder or depression 223, 225 and was classified as a body-
function impairment. The scale is reportedly valid and reliable 223, 226-227, although it has 
not been tested in persons with DM1. 
3.4.2.4 ECG recording (Studies II, IV) 
A standard 12-lead ECG (Siemens Sicard 460; Siemens Elema, Germany) recording 
was used to evaluate cardiac function. The recordings were classified by a cardiologist 
according to the standards of the Department of Cardiology at the Karolinska 
University Hospital, and rhythm and conduction abnormalities were documented. An 
abnormal ECG recording was classified as a body-function impairment. 
A 48h ECG examination, i.e. Holter monitoring, was used in Study IV. Participants in 
the training group were offered this assessment in to ascertain that there were no 
negative cardiac effects. 
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3.4.2.5 Spirometry (respiratory function test) (Study II) 
Spirometry was used for evaluating respiratory system functions (Spirolab II, MIR, 
Italy) following the recommendations of the American Thoracic Society/European 
Respiratory Society (ATS/ERS) 228-229. These were also used for severity 
classifications. Vital capacity (VC) when seated, percentage of predicted VC and 
ATS/ERS severity classification were documented. A spirometric abnormality was 
classified as a body-function impairment.  
3.4.2.6 The Åstrand-Rhyming test (cardiorespiratory fitness test) (Study II) 
The Åstrand-Rhyming test 230-231, a sub-maximal cycle ergometer test, was used to 
evaluate exercise tolerance functions, i.e. cardiorespiratory fitness. Based on estimated 
maximal oxygen uptake (VO2-max in ml x kg-1 x min-1), each person’s 
cardiorespiratory fitness was classified related to age and sex on a five-grade scale from 
low to very high 232. The Åstrand-Rhyming test is considered feasible for health 
surveys 233, and acceptable reliability has been reported 234. The validity of the test to 
predict VO2-max is somewhat conflicting, both over- and underestimations having been 
reported 233, 235. In general, however, data on the psychometric properties of the test are 
limited 236. 
3.4.2.7 The grip strength test (Study II) 
A standard hydraulic hand dynamometer (ref 43050, Chattanooga Group USA), 
equivalent to a Jamar dynamometer, was used for evaluating grip strength. Test 
procedures were standardized as described by Mathiowetz and co-workers and were in 
line with recommendations from the American Society of Hand Therapists 237-238. 
Three trials were performed for each hand, with a 10-15 s rest between trials. The mean 
value of the three trials, for each hand, was recorded. Measured mean values were 
compared to published normative values 237. Grip strength was considered to be below 
norm, and classified as a body-function impairment, when less than the mean minus 1 
standard deviation (SD) of the predicted hand-, age- and sex- normative value. 
Measures of grip strength with hand dynamometers are considered to be valid and 
reliable 238-241. Further, grip strength is a predictor of mortality, disability, 
complications and increased length of hospital stay 239. High reliability of grip strength 
with another instrument, the Grippit®, has been reported in adults with DM1 242. 
3.4.2.8 The timed-stands test (Studies II, IV) 
The timed-stands test (TST) 243 was used to evaluate lower-extremity performance, and 
thought of as a proxy for lower-extremity strength. Following a practice trial, the time a 
person took to rise and sit down 10 times as quickly as possible, without using the 
arms, from a chair without armrest (0.45 m seat height) was recorded. Studies 
providing normative data are scarce. However, upper time limits have been published 
and are suggested to separate normal from abnormal performance 243. The TST was 
compared to these published time limits. It was considered to be below norm, and 
classified as a body-function impairment, when the time exceeded the upper time limit 
of predicted age- and sex- normative values. The TST is reportedly a valid and reliable 
measure for lower-extremity function 243-244. There are, however, no published studies 
of its psychometric properties for persons with DM1.  
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3.4.2.9 The study-specific questionnaire on perceived effects (Study IV) 
To evaluate perceived effects of the exercise intervention in Study IV, participants in 
the training group answered a study-specific questionnaire after the training period. The 
questionnaire was developed by the author (MK) exclusively for study IV. Self-rated 
changes in fitness, strength, flexibility and daytime sleepiness were rated on a five-
grade scale ranging from much worse to much better.  
3.4.3 Activities and participation 
3.4.3.1 The nine-hole peg test (Study II) 
The nine-hole peg test (NHPT) was used to evaluate manual dexterity/fine hand use. 
The standardized test procedures and the test equipment were as described by 
Mathiowetz and co-workers 245. Following a first practice trial, the time taken to place 
nine pegs in a board and then remove them was recorded. The measured time for each 
hand was compared to published normative values 245. When the time was greater than 
the mean plus 1 SD of the predicted hand-, age-, and sex- normative value, the NHPT 
was considered to be below norm, and classified as an activity limitation. The NHPT is 
considered valid and reliable in various populations 245-247, although measurement 
errors are larger when hand function is very limited 247. Good-to-very-good intra- and 
inter-reliability were reported in adults with DM1 242 when manual dexterity/fine hand 
use was assessed with the Purdue Pegboard, a similar test to the NHPT. 
3.4.3.2 The timed up-and-go test (Study IV) 
The timed up-and-go test (TUG) 248 was used for evaluation of mobility and balance. 
Following a practice trial, the time taken to stand up from a chair with armrest (0.45 m 
seat height), walk three metres, turn, walk back and then sit down, was recorded. The 
persons sat with their back against a chair and feet behind a tape marker. They were 
instructed to rise on the word “go” and to walk at their preferred self-selected speed. 
Timing was begun when their back left the back of the chair and stopped when the 
buttocks touched the chair seat again. There are no normative values for younger 
adults. However, an upper time limit for normal performance in persons aged 60-69 
years has been set to 9 seconds 249. The test is considered valid and reliable 235, 248, 250-253 
although there are no published studies in persons with DM1. 
3.4.3.3 The six-minute-walk test (Studies II, III, IV) 
The six-minute-walk test (6MWT) 205, 254 was used to evaluate walking capacity and 
exercise tolerance 255. It was administered according to the ATS guidelines 256 on a 30-
metre track in a corridor. The beginning and end of the track, the turnaround points, 
were marked by orange plastic cones. The instruction was to walk as far as possible 
during the test. Persons were told that they were permitted to stop and rest if they felt 
too tired or breathless to continue, but to resume walking as soon as possible. 
Standardized encouragement was provided during the test, and information about the 
time left was given regularly. After six minutes, the person was told to stop, and the 
distance walked was measured. In the reliability part of Study III, three 6MWT trials on 
two separate occasions, one week apart, were performed. On all other test occasions, 
i.e. in Studies II, the feasibility part of III and in IV, the persons performed two trials, 
and the longest distance walked of the two was used in the analyses. Immediately 
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before and after each trial, perceived rate of exertion was rated on the Borg’s RPE 
scale® 257-258, which ranges from 6 (nothing at all) to 20 (maximal). In Studies II and 
III, the persons also rated their perceived rate of leg effort and shortness of breath on 
the Borg CR10 scale® 257-258, which ranges from 0 (nothing at all) to 10 (extremely 
severe). The instructions for the Borg scales were standardized 258 and given before 
each first trial.  
Studies providing normative values for the 6MWT, when administered as described 
above, are scarce. However, Troosters and co-workers 259 used a similar set-up as in 
Study II and propose an equation for calculation of predicted age- and sex- normative 
6MWT distances. Distances below 82% of the predicted can be considered abnormal 
according to the authors 259. Thus, the 6MWT distance was considered to be below 
norm, and was classified as an activity limitation, when less than 82% of the predicted. 
The 6MWT is considered valid and reliable in various populations 235, 251-253, 255, 260-261. 
There are, however, no studies on the feasibility and reliability of the test in persons 
with DM1.  
3.4.3.4 The Rivermead mobility index (Study II) 
The Rivermead mobility index (RMI) 262 was used to evaluate overall mobility. The 
scale’s 15 items range from turning in bed to running. One item, sitting unsupported, is 
rated by direct observation, and all the others are self-reported. Possible scores range 
from 0 to 15, a higher score indicating a higher level of mobility function. The RMI 
scores were dichotomized as independent, i.e. a full score, or dependent, i.e. a score 
between 0 and 14. The latter was classified as an activity limitation. The scale is 
considered valid and reliable in various populations 253, 263-265 and is recommended for 
use in DM1 218. 
3.4.3.5 The extended Katz ADL index (The Katz P- and I-ADL) (Study II) 
The extended Katz ADL index, without its continence item, was used to evaluate 
personal ADL (P-ADL) and instrumental ADL (I-ADL), as described by Sonn and 
Åsberg 266-268. The Katz P-ADL index consists of five items; feeding, bathing, dressing, 
toileting and transfer, and the Katz I-ADL index of four items; shopping, cleaning, 
cooking and transportation. Each item is assessed based on level of dependency and 
scored 0 if the person is dependent, and 1 if independent. Thus, the Katz P-ADL sum 
score range from 0 to 5, and the Katz I-ADL sum score from 0 to 4. Persons with a full 
score were categorised as independent. Any score less than full sum score was 
categorised as dependent, and was classified as an activity limitation. The scales are 
generic, and reliability and validity are considered to be sufficient 269. 
3.4.3.6 The Frenchay activities index (Study II) 
The Frenchay activities index (FAI) 270-271 was used to evaluate social and lifestyle 
activities. The scale consists of 15 items mainly concerning domestic chores, 
work/leisure and outdoor activities. Each item is rated on a 4-point scale (0-3) and 
scoring is, for most items, based on the frequency with which the activities are carried 
out, (activities which require involvement and initiative from the person). Possible sum 
scores range from 0 (inactive) to 45 (active). The FAI scores were compared to 
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published norms 272 and were considered to be below norm when less than the 25th 
percentile of the predicted age- and sex-norm value. The FAI scores were dichotomized 
as within-norm or below-norm, and the latter was classified as a participation restriction 
The scale is considered valid and reliable 265, 271-272, although Rasch analyses suggest 
revisions of items 273-274. The psychometric properties of the scale have not been 
evaluated in persons with DM1. 
3.4.4 Environmental factors 
3.4.4.1 Structured interview (Studies I, II, IV) 
Information on environmental factors was collected in structured interviews. Questions 
were asked about medicines, aids, home adaptations and personal care assistance. 
3.4.5 Personal factors 
3.4.5.1 Structured interview (Studies I, II, IV) 
Information on personal factors was also collected in structured interviews. Questions 
elicited age at diagnosis, inheritance pattern, additional health disorders, education 
level, civil and employment status. 
3.4.5.2 Form of DM1 (Studies I, II, IV) 
Persons were classified by form by their treating neurologist using the criteria described 
in the literature 2, 30-32. 
3.4.5.3 The muscular impairment rating scale (Studies I, II, III, IV) 
The muscular impairment rating scale (MIRS), a DM1-specific scale assessing 
muscular impairment 118, 204, was used for monitoring major stages of disease 
progression (expressed as disease severity in Study I). The MIRS is based on manual 
muscle testing, according to the modified medical research council scale (MRC) 275, of 
the neck flexors-, and six proximal and four distal muscle groups bilaterally. Severe 
weakness is defined as a MRC score <3/5. The five-point scale tallies with the usual 
distal-to-proximal progression of the muscular involvement where 1=no muscular 
impairment, 2=minimal signs, 3=distal weakness, 4=mild-to-moderate proximal 
weakness and 5=severe proximal weakness. Mild muscular impairment was defined as 
MIRS grades 1-3 and severe as MIRS grade 4-5. The validity and reliability of the 
MIRS have been supported by studies in persons with DM1 118, 204, and the scale is 
recommended for use in DM1 218. 
3.4.5.4 Anthropometric measures (Studies II, III, IV) 
To calculate body mass index (BMI), weight and height were measured. Classification 
of adult underweight (BMI<18.5 kg/m2), normal weight (BMI=18.5-24.9 kg/m2) and 
overweight (BMI≥25 kg/m2) was based on reference values from the WHO 276.  
Waist circumference was measured with a plastic measuring-tape midway between the 
lowest rib and the iliac crest. The sex-specific waist circumference cut-off values 
(women ≥0.88 m and men ≥1.02 m) from the WHO were used for classifying persons 
with a substantially increased risk of metabolic complications 276. 
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3.4.5.5 The physical activity scale (Study IV) 
Physical activity levels during the previous summer and winter half-years were 
evaluated on a six-grade scale 277-279, ranging from hardly any physical activity to heavy 
or very heavy exercise regularly and several times a week. 
3.4.5.6 The exercise self-efficacy scale (Study IV) 
The exercise self-efficacy scale (ESES) questionnaire 280-282 was used to evaluate self-
efficacy beliefs in Study IV. The scale assesses a person’s confidence in performing an 
exercise programme despite potential barriers, e.g. work schedule, physical fatigue, 
boredom related to exercise, minor injuries, other time demands, and family and home 
responsibilities. It consists of six items and possible scores range from 6 to 60, higher 
scores indicating greater confidence. The scale has been used in a Swedish primary care 
setting and is considered sufficiently reliable 280.  
3.4.5.7 The study-specific questionnaire on perceived experience (Study IV) 
To evaluate perceived experience of the exercise intervention in Study IV, participants 
in the training group answered a questionnaire after the training period. The 
questionnaire was developed by the author (MK) exclusively for Study IV. Perception 
of the form of the exercise programme was rated on a five-grade scale ranging from 
very bad to very good, and of the intensity on a five-grade scale ranging from much too 
easy to far too strenuous. The participants were also asked whether they could 
recommend the exercise programme to others with DM1. The questionnaire ended with 
an open question seeking comments and views about the intervention. 
3.4.6 Health-related quality of life 
3.4.6.1 The Short-form 36 health survey (Study IV) 
The Short-form 36 health survey (SF-36), standard Swedish version 1.0 145, was used to 
evaluate health-related quality of life (HRQoL). The scale consists of 36 items and all 
but one, change in health status, are grouped into eight health subscales: physical 
functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), 
general health perceptions (GH), vitality (VT), social functioning (SF), role limitations 
due to emotional problems (RE) and mental health (MH). Each subscale has a possible 
score from 0 to 100, a higher score indicating a better health state. Three of the 
subscales are bipolar, i.e. GH, VT and MH, and their middle values represent no 
negative evaluation of personal health, lack of symptoms of tiredness and absence of 
psychosocial disability, respectively. The SF-36 is a generic questionnaire and is 
considered both valid and reliable 145, 283-284. 
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3.5 FUNCTIONING AND DISABILITY 
3.5.1 Total number of body-function impairments, activity limitations 
and participation restrictions 
In Study I, the individual’s concurrent, i.e. total number of, body-function impairments, 
activity limitations and participation restrictions was calculated for each person by 
adding up the ICF categories that were rated as problems or difficulties. Thus, the total 
number could range from zero to 81.  
In Study II, the individual’s concurrent, i.e. total number of, body-function 
impairments, activity limitations and participation restrictions was calculated for each 
person by adding up the results classified as an impairment, limitation and/or restriction 
from examinations, tests and questionnaires. These were an abnormal ECG; a 
restrictive classification in spirometry; a below-norm value in grip strength, NHPT, 
TST and 6MWT; a dependent categorisation in RMI, Katz P-ADL and Katz I-ADL; a 
below-norm categorisation in FAI; presence of excessive daytime sleepiness in ESS; 
presence of fatigue in FSS; a case of anxiety disorders in HAD; and a case of 
depression in HAD. Those unable to perform the grip strength test, NHPT, TST or 
6MWT due to their physical condition, i.e. muscular impairment, were classified as 
having an impairment or limitation in that test. Thus, the total number could range from 
zero to 14. 
3.5.2 Cut-off values associated with functioning 
In Study II, associations were explored of measures of manual dexterity and of walking 
capacity with measures of activities and participation. Cut-off values associated with 
independence in personal and instrumental ADL, and within-norm participation in 
social and lifestyle activities were proposed by use of the following tests and 
questionnaires: NHPT, 6MWT, Katz P-ADL, Katz I-ADL and FAI. The NHPT was 
expressed as number of pegs per second in the analyses. For those unable to perform 
the tests, the NHPT was set to zero pegs/s and the 6MWT to zero metres. The Katz P-
ADL and I-ADL scores were dichotomized as independent, i.e. full score, or 
dependent; and the FAI scores as within-norm, i.e. score within normal range, or 
below-norm. 
3.6 EXERCISE INTERVENTION  
The intervention in Study IV consisted of individually-adapted group exercise training 
in the Friskis&Svettis® Open Doors programme. It was supported by music to guide 
the intensity and included aerobic activities; muscular strength and endurance 
exercises; balance and flexibility exercises; stretching and relaxation, see Figure 5. The 
programme could be adapted to the individual’s level of physical capability and 
capacity by for example performing the exercises with different pace and lever arms, 
and in varied positions, if necessary. Persons in the training group were asked to 
participate in the 60-minute Open Doors programme twice a week for 14 weeks, and 
they had two mid-day and two after-noon classes every week to chose between. They 
were also to take at least one brisk 30-minute walk every week, and to document these 
in an exercise diary. Acceptable adherence was defined as 75% attendance in the Open 
Doors programme, i.e. participation in at least 21 of 28 training sessions. Intended 
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intensity during the aerobic parts of the programmes was set to 60-80% of maximum 
heart rate, with maximum heart rate defined as 220 minus age. During the training 
period, actual heart rate was measured with a portable heart-rate recorder (Polar 
S610i™) on several occasions. To ascertain that there were no negative cardiac effects, 
persons in the training group were also offered a 48h ECG examination during the 
intervention period. Persons in the control group were advised to live their normal lives, 
and not to change physical activity behaviour during the study period. 
The 6MWT was chosen as primary outcome measure and the TST, TUG, ESS and SF-
36 as secondary outcome measures. The study-specific questionnaire on perceived 
effects was used to evaluate self-rated changes in fitness, strength, flexibility and 
daytime sleepiness in the training group. The ESES, the exercise diaries and attendance 
at Open Doors classes, and information from the study-specific questionnaire on 
perceived experience were used to explore the feasibility of the exercise regime. 
 
 
Figure 5. Schematic illustration of the group exercise programme and measured heart rate 
during a training session from one participant, a 43-year-old man.  
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3.7 STATISTICAL METHODS 
Drop-out analyses were performed with Fisher’s exact test for sex and an unpaired t test 
for age. Descriptive statistics were used to present data, i.e. mean and SD, median and 
interquartile range (IQR), minimum and maximum values, frequency and percentage. 
The significance level was p≤0.001 in Studies I and II, and p<0.05 in Studies III and 
IV. All analyses were performed using SPSS for Windows (release 15.0 or 18.0) except 
for the two-way repeated measures analysis of variance (ANOVA) in Study III, which 
used Statistica (release 6.0). See Table 3 for an overview of the statistical methods.  
Table 3. Overview statistical methods used. 
 Study 
I 
Study 
II 
Study 
III 
Study 
IV 
Descriptive statistics ● ● ● ● 
Receiver operating characteristic curves  ●   
Bland-Altman plots   ●  
Fisher’s exact test ● ●  ● 
Chi-squared test  ●   
Mann-Whitney U test ● ●  ● 
Unpaired t test ● ●  ● 
Wilcoxon matched-pairs signed-rank    ● 
Paired t test   ●  
Friedman test   ●  
Two-way repeated measures ANOVA   ●  
ICC 2.1   ●  
Spearman’s rank correlation    ● 
Linear mixed-model repeated-measurement analysis    ● 
 
3.7.1 Study I 
The qualifier scale was transformed to a three-grade scale for descriptive presentation 
of the modified ICF checklist results, and dichotomized in between group analyses. 
Fisher’s exact test and the Mann-Whitney U test were used to analyse differences in 
functioning and disability with regard to stages of disease progression (expressed as 
disease severity in article), i.e. between those with mild (MIRS 1-3) and severe (MIRS 
4-5) muscular impairment. The ICF domains were used in the descriptive presentation 
of persons with self-rated disability, who also rated environmental factors as 
facilitators. A person was regarded as having a disability if any category within the 
domain was rated as a problem or difficulty. Likewise, a person was regarded as 
perceiving the environmental domain as facilitating if any category was rated as a 
facilitator.  
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3.7.2 Study II 
Fisher’s exact test, the Chi-squared test and the Mann-Whitney U test were used to 
analyse differences with regard to stages of disease progression, i.e. between those with 
mild (MIRS 1-3) and severe (MIRS 4-5) muscular impairment. Descriptive statistics, 
the Mann-Whitney U test, and receiver operating characteristic (ROC) curves were 
used to explore associations of measures of manual dexterity and of walking capacity 
with measures of activities and participation.  
ROC curves can be used to assess the diagnostic accuracy of a test, to determine a cut-
off point at which optimal sensitivity and specificity are achieved and to compare the 
usefulness of two or more diagnostic tests 285. An ROC curve is obtained by calculating 
the sensitivity and specificity of a test at every possible cut-off point and plotting the 
sensitivity (the proportion of true positive results) on the y-axis against 1-specificity 
(the proportion of false positive results) on the x-axis 285-286. The area under the curve 
(AUC) reflects how well the test can distinguish between persons with and without 
disease or a certain characteristic 285. The closer the AUC is to 1, the better the test’s 
discriminative ability, and an AUC of 0.5 indicates that the test is no better than 
random. 
The ROC curves were used to visualise the ability of the NHPT and the 6MWT to 
discriminate between those who were classified as independent/within-norm and those 
who were classified as dependent/below-norm. The AUC and 95% confidence intervals 
(CI) were calculated. Cut-off values in the NHPT and 6MWT associated with 
independence in Katz P-ADL and I-ADL, and within-norm participation in FAI were 
identified by choosing those values at which optimal sensitivity and specificity, defined 
as those yielding the minimal value for (1 − sensitivity)2 + (1 − specificity)2, were 
achieved 285. The NHPT was expressed as number of pegs per second in these analyses. 
A value of zero was set for those unable to perform NHPT or 6MWT due to their 
physical condition. 
3.7.3 Study III 
In the reliability part of study III, Bland–Altman plots were used to check for 
systematic bias, outliers and heteroscedasticity 200-201. A two-way repeated measures 
ANOVA with two within factors (occasion and trial) was used to evaluate systematic 
differences in 6MWT distance and whether there was an interaction effect between 
occasions and trials. Relative reliability was assessed with ICC2.1 287 and absolute 
reliability with the SEM (defined as the within-subject standard deviation), the 
repeatability coefficient (defined as √2 x 1.96 x SEM) and coefficients of variation, i.e. 
SEM% (SEM/mean x 100) and repeatability% (repeatability/mean x 100) 199-200. The 
paired t test was used for analysing systematic changes in the mean between the best of 
the three trials on each occasion and also for the better of the first two trials on each 
occasion. The Friedman test 288 was used to test for differences in post-trial ratings on 
each occasion of perceived rate of exertion, leg effort and shortness of breath. 
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3.7.4 Study IV 
An intention-to-treat analysis approach was applied in Study IV. A linear mixed-model 
repeated-measurement analysis, using the compound symmetry covariance structure, 
was used for evaluating within-group, between-group and interaction effects for 
6MWT, TST and TUG data. For ESS and SF-36 data, the Wilcoxon matched-pairs 
signed-ranks test was used for within-group analyses and the Mann-Whitney U test for 
between-group analyses after intervention. Associations between exercise self-efficacy 
beliefs and attendance were analysed with descriptive statistics and Spearman’s rank 
correlation.  
3.8 ETHICAL APPROVAL 
Oral and written information was given and all participants gave their signed informed 
consent before enrolment. They were informed that taking part in the studies was 
completely voluntary, and that they could at any time, without stating any reasons, 
terminate their participation without it affecting their care. The studies were approved 
by the Regional Ethical Review Board in Stockholm and procedures were conducted in 
accordance with the Helsinki Declaration. 
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4 RESULTS 
4.1 PARTICIPANTS 
Drop-out analyses showed that there were no significant differences in sex or age 
between the persons with DM1 who participated in the studies (I, II, IV) and those who 
declined. Participant characteristics and personal factors are presented in Tables 4 and 
5. Data on environmental factors are presented in Table 6. 
The median time between occasions A and B in Studies I and II was four days. One 
person completed the questionnaires only on occasion B, and another was unable to 
come to this occasion. In Study IV, one control group member could not attend the data 
collection occasion after the intervention. He did, however, at that time, complete the 
questionnaires mailed to him. 
Table 4. Participant characteristic and personal factors. 
Studies I, II Study III Study IV 
 
 
n=70 
reliability
n=12 
feasibility
n=64 
training 
n=18 
control 
n=17 
 
mean (SD) 
range 
mean (SD)
range 
mean (SD)
range 
mean (SD) 
range 
mean (SD) 
range 
Age: years 
 
45 (13) 
19-70 
44 (12) 
28-68 
43 (13) 
19-70 
44 (11) 
20-60 
41 (15) 
20-65 
Age diagnosis: years 
 
32 (13) 
5-63 
 
32 (14) 
5-63 
  
 n n n n n 
Sex:  female 41 6 36 10 10 
  male 29 6 28 8 7 
Form of DM1: mild adult 2 0 2 0 0 
  classic adult 56 11 50 17 12 
  childhood 12 1 12 1 5 
Inheritance:  not known 13 3 12 3 3 
   maternal 24 3 22 5 7 
   paternal 33 6 30 10 7 
MIRS grade: 1 3 1 3 0 0 
   2 13 3 13 3 1 
   3 21 4 21 1 6 
   4 13 3 13 12 10 
   5 20 1 14 2 0 
Additional health disorders:      
   diabetes 3  3   
   goitre 3  2   
   psoriasis 2  2   
   myoma 2  2   
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Table 5. Participant characteristics and personal factors. 
Studies I, II Study III Study IV 
 
 
n=70 
reliability
n=12 
feasibility
n=64 
training 
n=18 
control 
n=17 
 n n n n n 
Education level: university 19  19 5 5 
   high school 35  31 8 3 
   < high school 16  14 5 9 
Civil status:       
  cohabiting with partner 31  29 9 9 
  single 22  20 3 6 
  divorced, separated, widow 17  15 6 2 
Employment:       
  work full 18  18 6 2 
  part time 8  8 2 4 
  full disability pension 31  27 7 6 
  other* 13  11 3 5 
BMI:  68  63   
 underweight 9 2 9 2 3 
 normal weight 29 6 29 9 10 
 overweight 30 4 26 7 4 
Waist circumference:  68  63   
 risk metabolic complications 27  22 7 5 
Hand dominance:      
 right 61  55   
 left 9  9   
Smoking/snuff-taking habits:      
 smokers 15  12 4 4 
 snuffers 14  4 1 3 
Physical activity summer: 69     
 mostly sitting to light 45  40 10 13 
 moderate 1-2 hours/week 17  17 6 3 
 moderate > 3hours/week to hard 7  7 2 1 
Physical activity winter: 69     
 mostly sitting to light 48  43 13 12 
 moderate 1-2 hours/week 16  16 4 4 
 moderate > 3hours/week to hard 5  5 5 5 
*other= studying, unemployed, retired 
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Table 6. Data from structured interviews concerning environmental factors. 
Studies I,II Study III Study IV 
 
 
n=70 
feasibility 
n=64 
training 
n=18 
control 
n=17 
 n n n n 
Medicines:      
 CNS stimulants 26 24 10 3 
 anti-myotonia 3 3 1 0 
Aids:      
 ADL  38 32 7 5 
 orthotic 20 20 5 3 
 mobility 25 19 1 1 
Home adaptations 31 25   
Personal care assistance 18 12   
 
4.2 FUNCTIONING AND DISABILITY (STUDIES I, II) 
Figure 6 presents the total number of categories from the modified ICF checklist rated 
as a problem and difficulty for each person. The median value was 10, IQR 6-19 for 
those with mild muscular impairment, and median 30, IQR 20-42 for those with severe. 
There was a significant difference (p<0.001) with regard to stages disease of 
progression. (Study I)  
Figure 7 presents the total number of classified body-function impairments, activity 
limitations and participation restrictions from tests and questionnaires for each person. 
The median value was 6, IQR 4-7 for persons with mild muscular impairment, and 
median 9, IQR 8-10 for those with severe. There was a significant difference (p<0.001) 
with regard to stages of disease progression. (Study II) 
Figure 6. The total number of categories from the modified ICF checklist rated as a problem 
and difficulty for each person, i.e. body-function impairments, activity limitations and 
participation restrictions, for those with mild (MIRS 1-3) and severe (MIRS 4-5) muscular 
impairment in Study I (n=70). The total number could range from zero to 81. 
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Figure 7. The total number of classified body-function impairments, activity limitations and 
participation restrictions from tests and questionnaires for those with mild (MIRS 1-3) and 
severe (MIRS 4-5) muscular impairment in Study II (n=68). The total number of could range 
from zero to 14. 
4.2.1 Body functions 
Twenty percent or more of those with DM1 perceived problems in 19 of the 29 body-
function categories from the modified ICF checklist. The median number of self-rated 
body-function impairments per person was 10, IQR 6-13. Excessive daytime sleepiness 
was rated as a problem by 80%, muscle power functions by 76%, and energy and drive 
functions by 66%. Further, 30% perceived severe-to-complete problems of muscle 
power functions and 23% of defecation functions; while 23% perceived pain as a 
severe or complete problem. Figure 8 presents percentages of perceived problem in the 
top-seven-rated body-function categories. (Study I) 
Impairments of excessive daytime sleepiness and fatigue; cardiac and respiratory 
functions; grip strength and lower-extremity performance were found (Table 7). There 
were five cases of anxiety disorders and none with depression. Twenty-eight persons 
were unable to perform the cardiorespiratory fitness test due to: inability to mount the 
ergometer cycle (n=10), leg-pain (n=7), unpredictable heart rate recordings (n=6), and 
perceived exhaustion (n=5). Four were unable to do the grip strength test and 15 the 
TST due to their physical condition, i.e. muscular impairment. (Study II) 
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Table 7. Results from measures of body functions (Study II).  
 n median (IQR) n (%) 
Epworth sleepiness scale, (score: 0-24) 69 9 (6-11)  
 excessive daytime sleepiness   19 (28) 
Fatigue severity scale, (score: 1-7) 69 4 (3-5)  
 fatigue   36 (52) 
Hospital anxiety and depression scale 69   
 Anxiety (score: 0-21)  5 (2-7)  
 cases of anxiety disorders   5 (7) 
 Depression (score: 0-21)  4 (2-6)  
 cases of depression   0 (0) 
ECG 70   
 conduction disturbances   21 (30) 
 arrhythmias   4 (6) 
 conduction disturbances and arrhythmias   1 (1) 
Respiratory function 68   
 VC % of predicted  75 (60-90)  
 normal   18 (27) 
 mild restriction   20 (29) 
 moderate-to-very-severe restriction   30 (44) 
Cardiorespiratory fitness, classified 40   
 very low to low   21  
 average   12 
 high to very high   7 
Grip strength, kg 66   
 right hand  8 (4-15)  
 body-function impairment, right hand   63 (95) 
 left hand  8 (4-14)  
Timed-stands test, s 55 24 (18-28)  
 body-function impairment   45 (82) 
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Figure 8. Illustration of relative frequencies of perceived problems, difficulties and facilitators 
in the top-seven rated-body-function, activity-and-participation and environmental-factor 
categories, n=70. (Study I) 
Persons with mild muscular impairment perceived less body-function problems than 
those with severe muscular impairment, and significant differences were found in the 
following four body-function categories from the modified ICF checklist: respiratory 
muscle, joint mobility, muscle power and gait pattern functions, (p≤0.001). There was 
also a significant difference in total number of body-function impairments per person 
between those with mild muscular impairment, median value 8, IQR 5-10 and those 
with severe, median value 12, IQR 9-14 (p<0.001). (Study I) 
Persons with mild muscular impairment performed better in tests than those with severe 
muscular impairment, and significant differences were found in tests of grip strength 
and lower-extremity performance (TST) (p≤0.001). (Study II) 
0% 20% 40% 60% 80% 100%
Support friends
Mobility aids
Transport services
ADL and orthotic aids
Social security services
Medicines
Support family
Walk around obstacles
Do housework
Climb stairs
Walk long distances
Walk different surfaces
Run
Lift/carry heavy objects
Pain
Articulation
Seeing
Myotonia
Energy and drive
Muscle power
Daytime sleepiness
Severe/substantial-complete Mild-moderate No
Body-function problem
Activity& participation difficulty
Environmental factor facilitator
    41 
4.2.2 Activities and participation 
Twenty percent or more of the persons with DM1 perceived difficulties in 23 of the 52 
activity and participation categories from the modified ICF checklist. The median 
number of self-rated activity and participation limitations/restrictions per person was 
10, IQR 3-19. Between 59% and 74% reported difficulties in physically-demanding 
mobility activities. The same activities, i.e. lifting and carrying heavy objects, running, 
walking long distances and on different surfaces, and climbing stairs, were rated as 
severe-to-complete difficulty by 27% to 54%. Few perceived difficulties in the domain 
community, social and civic life. Figure 8 presents percentages of perceived difficulties 
in the top-seven of rated activity and participation categories. (Study I) 
Activity limitations in manual dexterity, mobility including walking, and ADL, as well 
as participation restrictions in social and lifestyle activities were identified (Table 8). 
One person was unable to perform the NHPT and six the 6MWT due to their physical 
condition, i.e. muscular impairment. (Study II)  
Table 8. Results from measures of activities and participation (Study II).  
 n median (IQR) n (%) 
Nine-hole peg test, s    
 right hand 69 22 (20-29)  
  activity limitation, right hand   52 (75) 
 left hand 68 23 (21-31)  
Six-minute-walk test, m 64 465 (371-575)  
 activity limitation   49 (77) 
Rivermead mobility index, (score: 0-15) 70 14 (13-15)  
 dependent   52 (74) 
Katz personal ADL index, (score: 0-5) 70 5 (5-5)  
 dependent   11 (16) 
Katz instrumental ADL index, (score: 0-4) 70 4 (1-4)  
 dependent   27 (39) 
Frenchay activities index, (score: 0-45) 69 26 (19-32)  
 below-norm   36 (52) 
 
Persons with mild muscular impairment perceived less activity and participation 
difficulties than those with severe muscular impairment, and significant differences 
were found in 25 activity and participation categories (in the domains mobility, self-
care and domestic life) from the modified ICF checklist, (p≤0.001). There was also a 
significant difference in total number of activity and participation 
limitations/restrictions per person between those with mild muscular impairment, 
median value 3, IQR 1-9 and those with severe, median value 19, IQR 12-29 
(p<0.001). (Study I) 
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Persons with mild muscular impairment performed better in tests and questionnaires 
than those with severe, and significant differences were found in manual dexterity 
(NHPT), walking capacity (6MWT), mobility (RMI) and ADL (Katz P-ADL and I-
ADL) (p≤0.001). (Study II) 
Manual dexterity (NHPT) and walking capacity (6MWT) results for persons 
categorised as independent or dependent in Katz P- and I-ADL, and as within- or 
below-norm participation in FAI, are presented in Figure 9. For sensitivity and 
specificity of the proposed cut-off values, and AUC with 95% CI, see Table 9. The cut-
off values in the NHPT were 0.26 pegs/s (test time 35 s) for association with 
independence in Katz P-ADL, and 0.40 pegs/s (test time 22 s) for association with 
independence in Katz I-ADL and within-norm participation in FAI. Corresponding cut-
off values in the 6MWT were 246 m, 374 m and 486 m. (Study II) 
 
Table 9. Proposed cut-off values in manual dexterity (pegs/s) and walking capacity (m) for 
independence in personal and instrumental ADL (Katz P-ADL and I-ADL), and within-norm 
participation in social and lifestyle activities (FAI). Presented also are corresponding sensitivity 
and specificity values, and area under curve (AUC) with 95% confidence interval (95% CI). 
(Study II)  
    Nine-hole peg test, pegs/s 
 Katz P-ADL Katz I-ADL FAI 
Cut-off value 0.26 0.40 0.40 
Sensitivity 93 % 77 % 70 % 
Specificity 82 % 89 % 64 % 
AUC (95% CI) 0.94 (0.87-1.00) 0.88 (0.79-0.96) 0.69 (0.57-0.82) 
    
    Six-minute-walk test, m 
 Katz P-ADL Katz I-ADL FAI 
Cut-off value 246 374 486 
Sensitivity   93 %   91 %   61 % 
Specificity 100 %   70 %   75 % 
AUC (95% CI) 0.98 (0.95-1.00) 0.86 (0.76-0.96) 0.76 (0.64-0.87) 
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Figure 9. Boxplots of NHPT and 6MWT results for persons categorised as independent or 
dependent in Katz P- and I-ADL, and as within- or below-norm participation in FAI. The 
bottom of the box indicates the 25th percentile and the top the 75th percentile. The dark line in 
the box represents the median. T-bars extend to minimum or maximum value that is not outlier 
(otherwise to 1.5 times height of box). Outliers (●) are values more than 1.5 times the height of 
the boxes and extreme outliers (*) are values more than three times the height of the boxes.  
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4.3 CONTEXTUAL FACTORS (STUDIES I, II) 
4.3.1 Environmental factors 
Information concerning environmental factors, such as medicines, aids, home 
adaptations and assistance, collected by structured interviews is presented in Table 6. 
(Studies I, II) 
Twenty percent or more of the persons with DM1 perceived nine of the 23 
environmental factors from the ICF checklist as facilitators. Support from the 
immediate family, medicines, social-security services and aids for personal use in daily 
living were reported as facilitators by 50-60%. Further, 39% rated support from the 
immediate family, 37% transport services, 29% medicines and 29% social-security 
services as a substantial or complete facilitator. None of the 70 persons with DM1 used 
the barrier qualifiers when rating the 23 environmental factors. Figure 8 presents 
percentages of perceived facilitators in the top-seven of rated environmental-factor 
categories. (Study I) 
Persons regarded as having disability within a body-function or activity-and-
participation domain often rated an environmental domain as facilitating. If expressed 
as a percentage of the number of persons with disability, between 60% and 100% had 
rated one or more of the following environmental factor domains as being a facilitator: 
products and technology, support and relationships, and services, systems and policies. 
(Study I) 
Twenty-one of the 26 persons who reported prescribed CNS stimulants against 
excessive daytime sleepiness rated medicines as a facilitator. Further, 33 of 38 who had 
ADL aids, 14 of 20 who had orthotic aids, all 25 who had mobility aids, 20 of 31 who 
had home adaptations, and 17 of 18 person who had personal care assistance, rated 
these environmental factors as facilitators. (Study I) 
4.3.2 Personal factors 
Information concerning personal factors, such as participant characteristics, disease-
related and sociodemographic data, collected in structured interviews is presented in 
Table 3. (Studies I, II) 
Overweight was found in 30 persons and 27 had a waist circumference indicative of a 
substantially increased risk of metabolic complications. Over 60% reported low 
physical activity levels during summer and winter, and approximately 30% were 
physically active at least at a moderate level according to the physical activity scale. 
Persons classified as having severe muscular impairment were less active at this level 
than persons with mild muscular impairment, especially during summer (four with 
severe muscular impairment compared to 19 with mild, p=0.001). (Study II) 
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4.4 RELIABILITY AND FEASIBILITY (STUDY III) 
4.4.1 Reliability part 
Each person’s 6MWT distances from the three trials on the two occasions are presented 
in Figure 10. The two-way repeated measures ANOVA with two within factors 
(occasion and trial) analyses showed no interaction effect between occasions and trials. 
There was, however, a systematic difference between occasions (p=0.014), but not 
between trials (p=0.09). The individual’s best trial, that with the longest walked 
distance, differed between persons and occasions. Therefore, data from the best of the 
three trials and from the better of the first two trials for each person from both 
occasions were analysed. There was no systematic difference between occasions when 
used data came from the best trial (p=0.11) or from the better of the first two (p=0.15). 
The mean difference was 7 metres, with a 95% confidence interval (CI) of ± 10 metres, 
and an SD of the differences of 16 metres, with data for the better of the first two trials 
from each occasion. Using this data, relative reliability was high, with ICC2.1=0.99 
(95% CI 0.97-1.0). Further, absolute reliability values were low: SEM 12 metres, 
repeatability coefficient 33metres, and coefficients of variation 2% and 6% for SEM% 
and repeatability%, respectively.  
There was a small, but significant, increase in Borg RPE scores of perceived exertion 
between trials on both occasions (p<0.05). The median scores increased from 14 to 15 
and from 13 to 15 on occasions one and two, respectively. Perceived shortness of 
breath increased significantly between trials on the first occasion, from a median Borg 
CR 10 score of 4 to 5 (p=0.009). 
 
Figure 10. Each person’s walking distance on the three trials on the two occasions, n=12. 
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4.4.2 Feasibility part 
All but 12 of 64 persons performed two 6MWT trials in the feasibility part of Study III. 
The mean walking distance was 501 metres, SD 132 metres, and the individual walking 
distance varied from 193 to 744 metres. The most common stated reasons for inability 
to perform the second trial were “feeling too tired” or “lack of energy”. Nine of the 12 
persons were classified as MIRS 5, i.e. had severe proximal weakness.  
4.5 EXERCISE INTERVENTION (STUDY IV) 
There were no significant differences in mean 6MWT distance, TST time or TUG time 
within or between the training group and the control group, nor any interaction effects 
according to the linear, mixed-model, repeated-measurement analysis. Figure 11 
presents 6MWT distances from tests before and after the exercise intervention for 
training-group participants with acceptable adherence, i.e. at least 75% attendance, and 
low attendance; and for the control group. Six persons in the training group and two in 
the control group increased their 6MWT distance by ≥ 6%, while a decrease ≥ 6% was 
found in three persons in each group. Data from tests collected before and after the 
exercise intervention are presented in Table 10.  
Between-group analyses after the exercise intervention showed no significant 
differences in excessive daytime sleepiness or HRQoL, except for the MH subscale in 
favour of the control group (p=0.041). Within-group analyses showed no significant 
differences in excessive daytime sleepiness or HRQoL, except for a decrease in the 
vitality subscale in the control group (p=0.027). Data from questionnaires collected 
before and after the exercise intervention are presented in Table 11. 
 
Table 10. Data from tests before and after the exercise intervention.  
 Training group, n=18 Control group, n=17 
 mean SD min-max mean SD min-max 
Six-minute-walk test, m       
 before 527 103 398-752 507 100 276-665 
 after 536 116 363-783  505* 119 173-630 
Timed-stands test, s       
 before 23.8 6.6 9.9-39.1 22.7 6.7 14.7-36.1 
 after 23.2 7.2 8.5-36.3  23.1* 9.9 12.5-50.8 
Timed up-and-go test, s       
 before 7.9 2.2 4.0-12.3 7.1 1.5 4.8-10.2 
 after 7.4 2.2 4.2-13.0  7.1* 1.9 5.1-12.4 
*n= 16 
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Figure 11. The 6MWT distance from tests before and after intervention, (training group 
acceptable attendance n=11, training group low attendance n=7, control group n=16). 
 
Eleven of 18 persons in the training group had acceptable adherence to the Open Doors 
programme, i.e. attended at least 21 of requested 28 sessions, and another three 
participated between 15 and 17 times. According to the exercise diaries, eight persons 
took an additional 30-minute weekly walk in at least 11 of 14 weeks. The median time 
was 32 (IQR 20-44) minutes per session at a heart rate above or equal to 60% of 
calculated maximum, according to pooled data from 16 persons’ heart-rate recordings 
during training sessions. Analyses of 48h ECG recordings revealed that one person had 
periods of atrial arrhythmia, however not during or in connection with the training. This 
person was assessed by a cardiologist, received medical treatment and was allowed to 
complete the study. No other adverse effects were reported. Exercise self-efficacy 
scores in the training group correlated positively with attendance, non-significantly 
before the intervention (rs=0.38, p=0.117) and significantly after (rs=0.75, p<0.001).  
The training programme was labelled as “good” or “very good” by 16 of the 18 persons 
in the training group, and 17 could recommend this form of physical exercise for others 
with the same disease. The intensity was perceived as sufficient by 13, but too 
strenuous by four persons with proximal muscle impairment, MIRS 4-5. One person 
reported deterioration in muscle strength, and another perceived a worsening in daytime 
sleepiness. Improvements in fitness, muscle strength, flexibility and excessive daytime 
sleepiness were reported by 14, seven, 10 and eight persons, respectively.  
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Table 11. Data from questionnaires before and after the exercise intervention.  
 Training group, n=18 Control group, n=17 
 median IQR min-max median IQR min-max 
Epworth sleepiness scale (score 0-24)     
 before 12 8-15 4-18 8 4-13 1-18 
 after 12 8-16 2-19 9 6-14 0-21 
SF-36 health survey (score: 0-100)     
Physical functioning (PF)       
 before 63 48-76 10-95 65 40-90 15-95 
 after 60 45-84 20-95 60 48-70 20-95 
Role physical (RP)      
 before 50   0-100 0-100 75 38-100 0-100 
 after 50 25-100 0-100 100 13-100 0-100 
Bodily pain (BP)       
 before 73 39-85 20-100 74  41-100 31-100 
 after 62 41-88 12-100 62 41-92 31-100 
General health (GH)       
 before 54 34-73 10-87 62 38-72 10-92 
 after 52 20-68 10-82 65 34-75 10-90 
Vitality (VT)       
 before 55 39-61   5-80 55 40-68 5-90 
 after 45 39-58 10-75 40 25-63 5-80 
Social functioning (SF)       
 before 94 72-100 25-100 88 69-100 50-100 
 after 75 59-100   0-100 88 63-100 38-100 
Role emotional (RE)      
 before 67 33-100 0-100 100 67-100 0-100 
 after 100 58-100 0-100 100 67-100 0-100 
Mental health (MH)       
 before 80 68-89   44-100 72 66-92 48-96 
 after 72 67-85 40-92 84 80-92   36-100 
Exercise self-efficacy scale (score: 6-60)     
 before 35 23-44 10-51 25 21-35  8-49 
 after 30 21-42 11-49 31 20-34 13-44 
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5 DISCUSSION 
5.1 MAIN FINDINGS 
Functioning and disability in adults with DM1 were explored. Measures used included 
the modified ICF checklist and examinations, tests and questionnaires. Common 
problems and difficulties, and important environmental facilitators of functioning were 
described. That a wide variety of body-function impairments and activity limitations, 
and some participation restrictions were found underlines the multi-systemic nature of 
the disease and the vast impact it has on health. The individual’s concurrent, i.e. total 
number of, impairments, limitations and/or restrictions was high and differed with 
regard to stage of disease progression. Persons with severe muscular impairment had 
more impairments and limitations/restrictions than did those with mild muscular 
impairment. 
The 6MWT was a feasible and reliable outcome measure. Relative reliability, i.e. the 
ability to differentiate among persons tested, was high as was absolute reliability, i.e. 
the measurement error was low. Limits for the smallest differences to indicate a real 
change were suggested. The better of two possible trials on each test occasion was 
identified to be recommended for use as test result.  
The comprehensive group exercise training programme, the Friskis&Svettis® Open 
Doors programme, was feasible for our adults with DM1 classified as MIRS grade 2-4. 
The programme was well tolerated and no detrimental effects were shown. Intention-
to-treat analyses revealed no harmful or evidently beneficial effects. Many participants 
in the training group experienced subjective improvements and could recommend this 
form of physical exercise to others with the same disease. 
5.2 FUNCTIONING, DISABILITY AND CONTEXTUAL FACTORS 
(STUDIES I, II) 
Few of the studies on functioning and disability in DM1 describe contextual factors and 
also give a comprehensive view of concurrent body-function impairments, activity 
limitations and participation restrictions in the same sample of adults. Some 
shortcomings of previous reports are the lack of a genetically confirmed DM1 
diagnosis and that persons with other muscular dystrophies are included 94, 132-133, 136, 146, 
289-290. Other report mainly activity limitations and participation restrictions 130, 139. 
The persons with DM1 included in Studies I and II formed a heterogeneous sample 
concerning age, onset-forms and stages of disease progression, and this was reflected in 
the results. Some had multiple body-function impairments, activity limitations and 
participation restrictions, whereas others were practically unaffected by the disease. 
That a majority managed their daily activities and few perceived participation 
restrictions might seem remarkable, and it can be discussed whether this reflected the 
self-rating procedures and/or other factors. From self-rating you get the individual’s 
opinion or experience on the matter. This might not agree with, for example, a 
physiotherapist’s point-of-view. Further, living with a slowly progressive disease such 
as DM1 is a process of constant change and adjustment. Part of the adaptation process 
to a chronic disease consists of coping and a response-shift phenomenon. The response 
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shift includes a change in internal standards (recalibration), values (reprioritization) and 
conceptualization (re-conceptualization) 291-292: changing the way you think about 
things and adapting expectations, goals and ambitions to the current situation. That few 
participants in Study I reported difficulties in self-care activities when the modified ICF 
checklist was used might, consequently, be due to a response shift. The results can also 
be explained by the fact that performance, and not capacity, was rated. In the ICF, 
performance indicates what a person does in his or her current environment, with 
assistive devices if needed. Approximately half of the participants reported that they 
had ADL- and mobility aids, and home adaptations. The influence of these 
environmental factors was however unclear, since they were not rated as facilitators or 
barriers in relation to the activity and participation categories. The use of devices and 
tricks, as well as a high degree of satisfaction with self-care activities, is on the other 
hand also reported by others 130-131. 
Environmental factors play a central role for the understanding of a person’s 
functioning or disability 293. As stated in the ICF, disability is not a feature of the 
individual, but rather the result of the interaction between the person with a 
disease/disorder and the environment 38. That environmental factors are important for 
activity and participation is shown in various cohorts, including neurological and 
neuromuscular disorders 130-131, 294-295. That none of the participants in Study I reported 
any environmental barriers was surprising and in contrast to the findings of Gagnon and 
co-workers 139 who report barriers to participation only. This disparity might be 
attributable to differences in assessment methods and to differences between countries 
concerning the provision of aids, assistance, and government services. A majority of 
the persons with disability in Study I rated environmental factors as facilitators, and this 
indicates that they had access to physical and social environmental support. 
It is interesting that so few in Study I perceived difficulties in recreation and leisure 
activities. This is in contrast to Gagnon’s and co-workers’ 130 report that about a quarter 
of their DM1 study sample had participation restrictions. They consider participation in 
a domain to be disrupted if a person accomplishes it with difficulty and/or needs help. 
The participants in Study I rated if they perceived difficulty in becoming involved in 
the activities they wanted or chose to do. Thus, the discrepancy might be due to 
different assessment methods, to difficulties in addressing the role of participants’ 
choices and preferences in ratings, and/or a response shift as outlined above. Such 
differences might also explain why approximately half the persons with DM1 were 
classified as having participation restrictions in social and lifestyle activities, i.e. scored 
below norm FAI (Study II), although hardly any perceived restrictions when 
interviewed with the modified ICF checklist (Study I). Perhaps the FAI can be seen as 
an “objective” assessment related to frequency or duration, whereas the modified ICF 
checklist was a “subjective” assessment evaluating the importance of and the 
satisfaction with participation in the activities. Reports of satisfaction with recreation 
and leisure activities are, on the other hand, contradictory: low satisfaction is observed 
by Gagnon and co-workers 130 whereas Nätterlund and Ahlström 131 conclude that 
people with muscular dystrophy are satisfied since few wish for an improved situation.  
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That few participated in social and lifestyle activities while experiencing no 
participation restrictions might also be explained by the cognitive impairments and 
personality disorders known to be present in DM1. Examples of such are reduced 
executive functions, apathy, lack of initiative, indifference to a constrained life 
situation, avoidance behaviour and difficulties in social interplay 5, 33, 78. Evaluations of 
cognitive functions and personal factors such as coping would have been valuable, but 
were beyond the present scope.  
Limitations were found in physically demanding mobility and domestic-life activities, 
and activity limitations were related to muscle impairment. This  was expected, and in 
line with findings in other studies 130-133, 136, 146, 290. That few performed within normal 
range in the walking capacity test might be attributed to the distal foot-muscles 
weakness present already in the early stage of the disease and to the proximal lower-
limb muscle weakness common in later stages. Muscle strength is associated with 
walking ability in various neurological disorders 296-298, and with balance control and 
risk of falls in neuromuscular disease 134, 299-300. Although muscle strength training has 
positive effects on gait function in other neurological disorders 301-303, this has not been 
reported in DM1. Some improvements in gait and balance function are, however, 
reported in the 20 persons with DM1 who participated in a rehabilitation programme 
incorporating strength training 151.  
That muscle weakness is present in DM1 is well documented 122, 124-125, 304, and so far 
few authors report muscle-strength improvements after strength training 186, 188. The 
effect of strength training might, however, depend on initial muscle strength; if it is 
below 15% of normal, improvements are unlikely 305. A recent Cochrane review 
concludes that moderate-intensity strength training in DM1 is not harmful, but there is 
not enough evidence to state that it offers beneficial effects 182. Highlighted also is the 
need for more well-designed research on strength- and comprehensive aerobic exercise 
training. Exercise programmes might prevent additional disuse muscle atrophy and de-
conditioning in people with DM1, and thereby reduce the risk of secondary chronic 
conditions. Overweight, a waist circumference indicating a high risk of metabolic 
complications, and low physical activity levels were present in one-third of all 
participants in Study II, and approximately half of those with severe muscular 
impairment. This gave indications that these persons were at risk and might benefit 
from participation in an exercise programme, which was later evaluated in Study IV. 
There is no cure for DM1, thus the aim of treatment is to relieve impairments, reduce 
limitations and optimise participation. Finding factors related to activity and 
participation is therefore important, so that those at risk of limitations and restrictions 
can be identified. This gives an opportunity for early interventions. Specific threshold 
or cut-off values in hand function and mobility associated with functioning may 
therefore be valuable and useful for occupational therapists and physiotherapists in 
clinical practice. In Study II, such values were proposed, i.e. cut-offs associated with 
independence in measures of P- and I-ADL, and within-norm participation in social and 
lifestyle activities according to the FAI. These values might be used to identify persons 
risking activity limitation and participation restrictions, and also those with adequate 
functioning, who might not need interventions. The cut-offs can also serve as “red 
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flags”, indicating that persons below or near these values should be surveyed more 
closely concerning activities and participation. 
Fatigue and sleepiness are said to be two different, but interrelated, complex 
phenomena 306, and in DM1 are reportedly present both jointly and singly 63. Over two-
thirds reported that they had problems of excessive daytime sleepiness and fatigue 
(Study I), but fewer were classified as having impairments when the ESS and FSS, two 
standardized questionnaires, were used for assessment (Study II). The difference was 
especially large between perceived and classified occurrence of daytime sleepiness, 
80% versus 28%. This illustrates, once more, that what is captured certainly differs 
depending on the measure used for assessment. This might explain why no cases of 
depression were identified in Study II (the HAD questionnaire), when one-third in 
another Swedish DM1 sample had signs of clinical depression on the Beck Depression 
Inventory questionnaire 82. Excessive daytime sleepiness is reportedly associated with 
depression in DM1 63, 307. The current recommendations for treatment of depression 
include physical activity and exercise as important parts 170. That low physical activity 
levels are associated with fatigue in neuromuscular disease 67, 308, and with daytime 
sleepiness in e.g. older adults 309 and sleep apnoea patients 310, implies that physical 
exercise programmes might be a non-pharmacological approach worth considering for 
these impairments.  
Although cardiac and respiratory impairments were identified in approximately 40% by 
ECG and spirometry assessments (Study II), few participants perceived problems in 
these functions when the modified ICF checklist was used (Study I). This indicates that 
they were unaware of their impaired functions. Since both cardiac and respiratory 
impairments are known causes of mortality in DM1, patient education on warning 
signs, e.g. syncope, dizziness, palpitations and recurrent chest infections, should be 
emphasized. Whether chest physiotherapy and respiratory exercises can improve 
respiratory function in DM1 is uncertain. Two small studies report short-term effects of 
improved oxygen saturation 311-312, but there is so far no strong evidence to support 
various respiratory therapies in neuromuscular disease 313. 
In the present work functioning and disability were explored with regard to different 
stages of DM1, and the MIRS 118, 204 was used to categorize participants into two 
groups depending on degree of muscular impairment: MIRS grades 1-3 for mild 
muscular impairment and MIRS grades 4-5 for severe. It was no surprise that 
significant between-group differences were found in tests and questionnaire reflecting 
functions where muscle strength is important. More interesting was the lack of 
significant differences in cardiac and respiratory functions, and in excessive daytime 
sleepiness and fatigue. This result is in line with others’ findings 65, 70, 96, 99 and has 
implications for assessment and management in clinical practice. Consequently, these 
functions should be monitored regardless of the degree of muscular impairment.  
There was a lack of significant differences between the groups in ratings of myotonia 
and pain when the modified ICF checklist was used. That myotonia was rated as a 
problem by approximately two-thirds in Study I contrasts to the notion that it is a 
problem of less extent occurring mostly in mildly affected persons 5. That pain, and 
even severe pain, was so frequent in participants regardless to stages of the disease 
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stage, was somewhat unexpected. On the other hand, pain is currently recognized as a 
common problem in people with neuromuscular disease 90-91 and the causes are said to 
depend on type of disease and level of muscle impairment and mobility 314. The causes 
and management of pain in DM1 have, however, not been studied in detail, and there is 
a need for additional research. 
The individual’s total number of body-function impairments, activity limitations and 
participation restrictions was high, especially in those with severe stages of the disease. 
This implies that a multi-professional approach is needed for optimal care. Special 
centres exist for adults with neuromuscular disease in some parts of Sweden, for 
example Gothenburg, but there may be a lack of appropriate health-care services for 
persons with DM1 elsewhere in Sweden. It would therefore be valuable if national 
guidelines on the standard of care were to be formulated and implemented for people 
with DM1. 
5.3 RELIABILITY AND FEASIBILITY (STUDY III) 
The performance of many repeated trials of the 6MWT on one test occasion is not 
desirable in the clinic or in research. The findings in Study III, that two trials were 
sufficient, and that the trial with the longest walking distance should be used as the test 
result, are therefore of significant value. Many studies report that practice trials are 
needed to get reliable test results 205, 254-255, 315, and a practice trial should be considered 
according to the ATS guidelines for the 6MWT 256. Despite the small study sample in 
Study III, relative reliability tallied with findings in other neurological disorders, where 
ICC coefficients range from 0.96 to 0.99 251-252, 260-261. Absolute reliability results were 
used to describe the minimal amount of change that was not due to variation in the 
measure, and thus might indicate a real change for an individual or a group of persons 
with DM1. Both SEM and repeatability% values were a bit lower than in other 
neurological disorders where SEM varies from 19 to 31 metres and repeatability% from 
13% to 20% 251-252, 260-261. This might be due to the lack of practice trials 251-252, 260-261 
and standardized encouragement 251 in the other studies. The present Study III findings 
suggest that a difference of 33 metres or 6% might indicate a real change for an 
individual with DM1. 
The 6MWT was feasible in DM1: the test was easy to administer and score, took little 
time, the cost was low, it was considered safe, and all those able to walk could perform 
it. However, nine persons classified as MIRS 5, i.e. having severe muscular 
impairment, felt too tired or lacked the energy to perform two trials on the same 
occasion. This important finding suggests that persons with severe proximal weakness 
need sufficient rest between trials, or perhaps should be tested on different occasions. 
5.4 EXERCISE INTERVENTION (STUDY IV) 
Evidence-based recommendations regarding physical exercise in DM1 must be based 
on knowledge of feasibility and the effects of various exercise programmes. Study IV 
therefore addressed these aspects by evaluating a comprehensive group exercise 
training programme, the Friskis&Svettis® Open Doors programme. That many 
characterised the training programme as “very good”, would recommend it to others 
with DM1, and reported subjective changes for the better in fitness, strength, flexibility 
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and excessive daytime sleepiness indicate that this type of exercise regime may be 
appropriate. The aim and advantage of the programme were that participants could 
adapt exercises and intensity to their own level of physical capability and capacity. This 
might explain why participants with such varied muscular impairment, i.e. MIRS 
grades 2 to 4, rated the intensity level as sufficient. Four persons with proximal 
weakness, however, found the programme too strenuous. Two of these had severe 
proximal weakness and participated in one and three sessions, respectively. Although 
the reason for their low attendance is not known, it can be speculated that the ambition 
of individualising the group training programme was not fulfilled, and that there might 
be a need for either special introductions or groups for persons classified as MIRS 
grade 5.  
To improve exercise adherence in Study IV, a number of strategies were applied such 
as positive reinforcement, exercise diaries and regular contact with participants for 
feed-back. These were the same as some of the reported strategies that enhance exercise 
adherence in adults with chronic musculoskeletal pain 316. However, the time and place 
for the group exercise training sessions might have hampered adherence, since it was 
not possible to have evening classes or to use other locations than the hospital. 
Adherence is a possible threat to the validity and efficacy of any exercise intervention 
study. This is especially true in DM1, where cognitive and behavioural problems, such 
as lack of motivation and initiative, fatigue and avoidance behaviour, are common 
aspects of the disorder 33, 78. Adherence is better in supervised group training than in 
home-based training 191-192, and supervised training is therefore recommended 186, 317. 
Thus, it was not surprising to find better adherence with the Open Doors classes than 
with the requested additional weekly walks. The most common reason for not attending 
classes was illness, and the overall impression was that the motivation level for group 
training was high. A benefit of group training, besides being cost-effective, was the 
opportunity for the participants to meet others with the same disease. This is recognised 
as important for persons with muscular dystrophies 191, 318. At the same time, meeting 
persons with worse symptoms, and perhaps then realising the possible course of the 
disease, can also be bothersome. This might have been the reason for the low 
attendance of a newly-diagnosed person with few symptoms of the disease. However, 
most participants in the training group seemed to appreciate the access to social 
support. Social support, in the shape of social persuasion and comparison, also 
influences self-efficacy beliefs, which operate as important personal determinants of 
human behaviour 319-320. 
Self-efficacy refers to a person’s confidence and beliefs about his or her capability to 
organize and execute the actions required to attain a wide range of goals 321. These 
beliefs are influenced by previous experience, observation of successful or unsuccessful 
attainment by others, persuasion by others, and by how associated experience, i.e. 
somatic and emotional states, are interpreted 321. Self-efficacy correlates with 
participation in physical activity, and is a determinant of exercise adherence and 
exercise behaviour in adults 282, 322-324, and a predictor of exercise adoption 322. Self-
efficacy beliefs should be assessed against gradations of challenges or barriers to 
successful performance 321. In Study IV, the persons’ exercise self-efficacy beliefs were 
evaluated by assessing their confidence in performing an exercise programme despite 
potential barriers such as work schedule, physical fatigue, boredom related to exercise, 
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minor injuries, other time demands, and family and home responsibilities. The pattern 
of change in exercise self-efficacy scores differed between the two groups. Whereas the 
median score increased in the control group, a decrease was found for the training 
group. That a high positive correlation was found between attendance and exercise self-
efficacy scores rated after the intervention in the training group indicates that they 
changed their beliefs over time. Perhaps participants in the training group became more 
aware of their abilities to engage in exercise under varying conditions. Further, their 
self-efficacy beliefs at that point were influenced by the experience of the exercise 
intervention, and this might have made their assessments more realistic. It is important 
to examine exercise self-efficacy in conjunction with other personal and environmental 
variables to identify persons likely to adhere to exercise programmes, and to identify 
potential barriers. Recently, such barriers to and constraints on exercise and physical 
activity have been reported for neuromuscular disease 176, and for long-term 
neurological conditions 320. Lack of energy and motivation, pain, feeling self-conscious 
at leisure centre/gym, and economics, are specific barriers to exercise in persons with 
neuromuscular disease 176. Low exercise self-efficacy beliefs, lack of supporting 
physical environment and lack of support and understanding from the social 
environment are factors that limit engagement in physical activity for people with long-
term neurological conditions 320.  
That the Friskis&Svettis® Open Doors programme included endurance, strength, 
flexibility and balance components indicates that it was a well-rounded physical 
activity programme. This is in line with what is recommended for general health and 
well-being in older adults with chronic disease, and for those with low physical activity 
levels 325. Important factors for producing training effects are frequency, intensity and 
duration of exercise 172. The necessary overload stimulus is provided by a combination 
of these factors, and the higher the stimulus the higher the training effect, and vice 
versa. To reach the recommended volume and quality of exercise for developing and 
maintaining cardiorespiratory and muscular fitness 172, 326, participants in the training 
group were asked to attend the Open Doors classes twice a week and to take at least 
one 30-minute brisk walk every week. The intensity during the aerobic parts of the 
programme was targeted to be at least moderate, 60-80% of maximal heart rate, and 
pooled data from heart-rate recordings indicates that the desired intensity was achieved. 
It can, however, be argued that both frequency and intensity were too low to generate 
training effects. At the same time, the aim was to study feasibility and effects of a 
programme that would apply in the real world, and reflect a frequency level that 
persons with DM1 could incorporate and maintain in their daily lives. Further, the 
achieved intensity was really up to the participant, even if the music and the group-
leader guided and encouraged participants to work up to the intended intensity in the 
various parts of the training programme.  
No adverse events were reported during the study. However, the 48h ECG 
examinations revealed that one person had periods of atrial arrhythmia, although not 
connected to the training sessions. This implies the importance of thorough cardiac 
examinations, and that both conventional and 48h ECG monitoring should be 
performed regularly. Important findings were, however, that no negative cardiological 
effects were found, and that the training programme seemed to be well tolerated. 
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Despite a significant between-group difference in the SF-36 mental health subscale, no 
significant within-group differences were found. The mental health subscale is, 
however, bipolar, any value above 50 indicating absence of psychosocial disability. The 
clinical value of the difference was therefore uncertain. The observed changes in 
subscale scores were not interpreted as an effect of the exercise intervention. The lack 
of other statistically significant differences does not per se mean that there were no 
effects, but merely that an effect of zero cannot be ruled out 327. Even if significant 
differences were to be found, this is not the same as clinically important or relevant 
differences. There are no exact rules for how to decide what makes a difference 
clinically important. It is arguably what clinicians and/or patients judge as clinically 
important. Sometimes such judgements are based on knowledge of an outcome 
measure’s clinometric property. Based on the results in Study III, a difference equal to 
or over 6% in 6MWT distance was chosen to indicate a real change for an individual 
with DM1. Using this cut-off six persons, of whom five had at least 75% attendance, 
increased their walking distance in the training group compared to two controls. 
Although no sub-group analyses have been performed, a possible dose-response 
relationship might explain some of our results. 
It is essential to evaluate exercise regimes that are available outside the health care 
system. With limited resources, it is not possible or even desirable that all persons with 
DM1 perform their physical exercise at a physiotherapy clinic. Study IV is therefore 
unique, as it evaluated the feasibility and effects of a comprehensive group exercise 
programme that is available at many local Friskis&Svettis® sport associations in 
Sweden. The group exercise training programme seemed to be well tolerated, although 
some persons with proximal muscle impairment found it too strenuous. However, 
barriers such as costs and feeling self-conscious in leisure centres or gyms, are 
identified constraints to exercise in persons with neuromuscular disease 176, implying 
that it might be difficult for some persons with DM1 to participate in exercise regimes 
outside the health care system. That persons with mild muscular impairment can be 
recommended exercise regimes such as the Friskis&Svettis® Open Doors programme 
is an experience from the exercise intervention. However, it might be better for persons 
with severe muscular impairment to perform physical exercise within a health-care 
setting. 
5.5 METHODOLOGICAL CONSIDERATIONS 
5.5.1 Study sample 
Although there is no neuromuscular centre in the Stockholm County Council area, 
many persons with DM1 have contact with neurologists at the Karolinska University 
Hospital. A majority of the present participants were identified from the outpatient 
clinics at this hospital’s Department of Neurology. With an estimated prevalence of 10 
per 100 000, approximately 200 persons would be expected to be found in the 
Stockholm County Council area. Thus, many persons with DM1 living in the region 
did not participate. Whether these persons, or the persons who declined participation, 
differed significantly from the participants is not known. It can be speculated that 
persons who lack contact with a neurologist might be less affected by the disease, and 
that those declining participation might be either less or more severely affected. Drop-
out analyses could, however, only be performed on the variables sex and age, due to the 
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ethical permission. The inclusion of persons with childhood or adult-onset forms 
resulted in a heterogeneous sample, which can be thought of as a shortcoming. Despite 
this, the study sample seemed representative of adults with DM1 in comparison with 
previously reports from Swedish and Canadian cohorts 130, 132, 136, 139, 146.The selection 
of participants in the reliability part of Study III was intentional: persons were selected 
to represent the different sexes, ages and stages of disease progression, which supports 
the idea that the findings may also be relevant for other adults with DM1, even though 
the study sample was small, only 12 persons. 
A major problem in clinical trials of rare diseases is sample size and sample selection. 
Adults with DM1, also those with the childhood form, were eligible for Study IV in 
order to recruit as many participants as possible. However, only 35 of those fulfilling 
the criteria for participation were interested. This resulted in a heterogeneous group 
with respect to onset form and muscular impairment. This may be a shortcoming, but it 
reflects reality and the aim was to explore the feasibility of the Friskis&Svettis® Open 
Doors programme for the DM1 population. The consequence of this small and 
heterogeneous sample was an underpowered study. Multi-centre studies are therefore 
currently recommended for exercise intervention research on persons with physical and 
cognitive disability 328. However, underpowered studies are not without value since 
their results can contribute to the larger body of evidence 329.  
There is always a risk of selection bias in intervention studies, and especially in those 
involving physical activity and exercise. People who are willing to participate in 
exercise-related research are often younger and/or have a better functional level than 
the entire relevant population 328. This might also be true for participants in Study IV. 
However, examples of reasons for declining were “already exercising”, “lack of time or 
interest”, implying that both physically active and inactive persons chose to not take 
part. The results from Study IV cannot, however, be extrapolated to the entire DM1 
population, since this was not represented. However, the findings may be representative 
of persons with DM1 who have been screened for cardiac involvement, have distal-to-
mild/moderate proximal muscle impairment and no severe cognitive impairment.  
5.5.2 Design and procedures 
Cross-sectional design studies contribute to research evidence by identifying the 
occurrence and severity of various health problems. This design was therefore chosen 
in Studies I and II to gather information on functioning, disability and contextual 
factors in adults with DM1. However, changes occurring over time cannot be captured 
with this design nor is it applicable to studying cause-effect relations. The test-retest 
design, with repeated trials on two occasions, used in Study III might seem 
unnecessarily complex. It was, however, applicable and adequate for its purpose since 
learning and/or fatigue effects, and the need for familiarisation trials were to be 
explored. To provide the most reliable and highest form of evidence for evidence-based 
practice, a randomized controlled trial (RCT) design was chosen for evaluating the 
feasibility and effects of the exercise intervention in Study IV. The RCT design is 
considered the gold standard for evaluating the effectiveness of interventions. Great 
care was taken to fulfil the criteria for a high quality RCT considering design, conduct, 
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and analysis; hence the guidelines from the CONSORT (Consolidated Standards of 
Reporting Trials) Statement 330 were applied for reporting in Study IV.  
That the structured interviews and the standardized tests and questionnaires, in Studies I 
and II, were administered by the same person ensured that variations in outcomes were 
not likely to be caused by differences in administration. The data collected was, 
however, fairly extensive. This might have been tiring for the participants, even though 
evaluations were spread over two occasions, and the day and time were suited to their 
requests. Thus, it is possible that the large number measures influenced the results. 
Information and instructions were given, and procedures were performed, according to 
study-specific protocols in Studies I-IV. This shows that precautions were taken to 
ensure that any measured variability would not be due to bias caused by external factors 
such as the test situation and evaluators. The evaluators, two experienced 
physiotherapists, in Study IV were blinded to group allocation and had no further 
involvement in the study. The group training and the data collections were performed in 
different premises at the hospital (different buildings several blocks apart), so it was 
unlikely that the evaluators were aware of group allocation. Participants were also 
informed that they were not to reveal group affiliation at the evaluation after the 
exercise intervention period.  
The lack of standardized outcome measures, evaluated concerning validity, reliability 
and responsiveness in the DM1 population, resulted in a selection of measures based on 
previous knowledge and experience, literature reviewing, and psychometric properties 
found in the general population and in people with other neurological disorders. This 
can be considered a limitation, but it is not unusual in studies in people with rare 
diseases. The tests and questionnaires were, however, well-known both in the clinical 
settings and in the research context. Both floor and ceiling effects were found among 
the chosen measure. Such effects are present when a high proportion of the study 
sample have the maximum or minimum score, respectively. It is suggested that these 
effects are present if more than 15% score the highest or lowest possible score 331. 
Ceiling effects were for example found in the RMI, the Katz P- and I-ADL index. It 
can be argued that the TST and the Åstrand-Rhyming test had floor effects since many 
participants could not perform these tests.  
As for the TST, quite a few of those classified as MIRS 4-5 had difficulties to rise and 
sit down 10 times in a row. A five-times sit-to-stand test is commonly used in elderly 
people and it has been suggested that it has the broadest application as a functional 
strength test 332-333. This test has a predictive value for recurrent falls in community-
living elderly people 334. Given the impaired function present in DM1, this latter sit-to-
stand test might be more appropriate, even though the normative reference values are 
for adults over 60 years of age 333.That excessive daytime sleepiness was possibly 
underestimated when the suggested ESS cut-off score of ≥11 was used, indicates that 
the validity of the scale might be questioned. Even though the scale is recommended as 
an outcome measure in DM1 218, several authors point out that the ESS is not the most 
appropriate and sensitive measure to capture the phenomenon in DM1 63, 68, 217, 335. 
Assessment of grip strength is another recommended outcome measure in DM1 218 and 
is reportedly useful for clinical trials 336. The value of Jamar dynamometer assessments 
might however be of limited value if persons are as weak as many in Study II. Even 
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though the measurement error of the test is not known for people with DM1, it is 
reported to be 4.8 kg in healthy persons 241. Hence, this method of grip strength 
assessment might not be sensitive enough for clinical trials. That many persons with 
DM1 were unable to perform the Åstrand-Rhyming test for reasons such as leg pain, 
perceived exhaustion and unpredictable heart rate recordings indicates that this test 
might not suitable for the whole DM1 population.  
The FAI was used as a measure of participation in social and lifestyle activities. 
Whether this scale captures the dimension of participation can be questioned, as scoring 
is for most items based on the frequency with which the activities are carried out. 
However, these activities are such that they require involvement and initiative from the 
person. Participation is in the ICF defined as involvement in a life situation. Thus, it 
may be argued that FAI can be used for assessment of participation. 
That self-rating procedures were applied when the modified ICF checklist and the 
questionnaires were used might be thought of as a shortcoming. Since mental functions 
such as intellectual, attention, memory, thought and higher-level cognitive functions 
were not explored, it is unknown whether all persons with DM1 in the present work 
had the prerequisites to understand all the questions. However, the individual’s own 
perception should not be disregarded: it is significant and can assist in the development 
of health services. The overall impression was that most of the questionnaires worked 
even if the SF-36 had a rather complex language. 
Although the ICF checklist was modified to capture information thought to be 
important for persons with DM1, possibly important categories of mental functions, 
such as intellectual and emotional functions, and of interpersonal interactions and 
relationships such as family and intimate relationships, were not assessed. At the same 
time redundant information was collected in the mobility and self-care domains. ICF 
core sets are shortlists of domains considered relevant for describing health conditions. 
Wynia and co-workers 337 propose 68 ICF items considered to be relevant for persons 
with neuromuscular disease. The modified ICF checklist comprised most of these 
items. Even if a DM1-specific core-set were developed, a barrier to its clinical use 
would be the ICF language. Experience from the data collection in Study I was that the 
ICF categories had to be expressed in everyday language to be understandable. Further, 
that some symptoms or terms used in the clinic do not really fit the ICF. For example 
there is no obvious ICF category for excessive daytime sleepiness and fatigue which in 
Study I were mapped to consciousness functions, and energy and drive functions, 
respectively. Nor is there a category for balance which might be said to come under the 
mobility domain, activity and participation component. It would therefore be a good 
idea to develop specific ICF assessment tools or to use the proposed linking rules 338 
and “translate” existing outcome measures to ICF language. The ICF can, however, 
only be used to identify “what?” but not “how?” to measure. 
The selection of primary outcome measure in Study IV was based on the assumption 
that it would mirror endurance and functional exercise capacity. Although the results 
from Study III showed that the 6MWT was feasible and reliable in DM1, there are 
issues to consider. The distance walked is determined by the walking speed. An 
increase in stride length and/or cadence will increase the walking speed and thereby the 
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walking distance. Crucial for accomplishing this is distal lower-limb muscle strength. 
Ankle dorsiflexion and plantar flexion strength correlate significantly with both 
walking speed and the rate of stumbles and falls in persons with DM1 134. Hence, a 
person with severe distal weakness might not be able to increase walking speed without 
stumbling and falling. Another aspect of the 6MWT is that motivation and cooperation 
are important for maximal performance. As lack of initiative and motivation, and 
apathetic attitudes can be features of DM1, special precautions may be needed when 
administering the tests. The evaluators therefore stressed that the participants were to 
seek their best possible performance. The order, instructions, and encouragement were, 
however, standardized according to a study protocol and the same on both data 
collection occasions, to avoid biasing the results. All participants understood and 
completed the tests, but it can be speculated that some might not have performed at 
their maximal level. 
5.5.3 Statistical considerations 
Descriptive statistics were employed in the present work to give an overview of 
functioning, disability and contextual factors. Non-parametric statistical methods were 
used predominately since the data level was mostly ordinal and the distribution skewed. 
Parametric statistical methods were, however, used for ratio-data fulfilling the 
requirements for such tests.  
The classification of body-function impairments, activity limitations and participation 
restrictions from test and questionnaire results in Study II, was based on predicted age- 
and sex-normative values, which is important in between-group comparisons of 
variables known to be influenced by age and sex. The rationale for choosing the mean 
minus-or-plus 1 SD or the 25th percentile as cut-off was that most studies presenting 
normative values are based on rather small study samples, and if for example 2 SD had 
been chosen there would have been a risk of underestimating 
impairments/limitations/restrictions. The significance level was set to p≤0.001 in 
Studies I and II since so many analyses were performed and false significance was to 
be avoided (type I error).  
An advantage of linear mixed-model repeated-measurement analysis is that the analysis 
can handle missing data. The only missing data in Study IV was test results from data 
collection after the exercise intervention for one person in the control group. That 
walking distance in the 6MWT, the primary outcome measure in Study IV, ranged 
from approximately 200 to 800 metres with a mean (SD) around 500 (100) metres is 
explained by the small and heterogeneous study sample. It is evident that a very large 
study group is needed if statistically significant differences are to be shown in a sample 
with such variable distribution. Thus, there is a risk of a type II error in Study IV, i.e. a 
risk of getting a false statistically non-significant difference between the control and 
training groups.  
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5.6 CONCLUSIONS AND CLINICAL IMPLICATIONS 
Common body-function impairments, activity limitations and participation restrictions, 
and facilitators of functioning, were identified in adults with DM1 using various 
measures and methods. Excessive daytime sleepiness, muscle weakness and fatigue 
were common impairments and activity limitations were most frequently found in 
physically demanding mobility activities. Few reported participation restrictions. 
Support from the immediate family seemed to be the most important facilitator for 
functioning. The individual’s total number of impairments, limitations and restrictions 
was high and there was a difference with regard to stages of disease progression. 
Persons with severe muscular impairment had more impairments and 
limitations/restrictions than did those with mild muscular impairment. Differences with 
regard to disease progression were found in various body-functions and activity and 
participation categories, mainly such that required muscle strength. Lack of differences 
with regard to disease progression was found in functions of the cardiovascular and 
respiratory systems, and mental functions (excessive daytime sleepiness and fatigue), 
implying that these functions should be monitored regardless of the degree of muscular 
impairment. The finding of a wide variety of body-function impairments and activity 
limitations underlines the multi-systemic nature of the disease and the vast impact it has 
on health. It further implies that a multi-professional approach is needed for optimal 
care. The information can be used for developing clinical practice and for health 
promotion for people with DM1. 
The 6MWT was both feasible and reliable for use in adults with DM1. Recommended 
is a practice trial followed by a second trial on the same test occasion, and that the 
better of these two possible trials be used as test result. Persons with severe proximal 
weakness need, however, sufficient rest between trials. It is suggested that the minimal 
detectable difference for a change not due to measurement error be 33 metres or 6% for 
an individual with DM1. 
A comprehensive group exercise training programme, the Friskis&Svettis® Open 
Doors programme, was feasible for adults with DM1 who had been screened for 
cardiac involvement, had distal or mild-to-moderate proximal muscle impairment and 
no severe cognitive impairments. The programme was well tolerated and no 
detrimental effects were found. Although intention-to-treat analyses revealed no 
evident beneficial effects, many participants in the training group perceived 
improvements and could recommend this form of physical exercise for others with the 
same disease. 
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5.7 FUTURE RESEARCH 
There is a lack of standardized outcome measures evaluated in the DM1 population. 
Future studies are therefore needed to assess validity, reliability and responsiveness of 
existing measures and possibly also to develop new disease-specific measures. 
The phenomena of fatigue and excessive daytime sleepiness are complex in DM1 and 
further studies are required to explore these concepts and to develop possible treatment 
strategies for people with DM1. 
Pain is recognized as a frequent and common problem in people with neuromuscular 
disease, including DM1. Few studies describe factors and/or situations that might 
aggravate or lower the level of pain, and there is, accordingly, a need for additional 
research to improve the understanding and management of pain in DM1. 
A major problem in clinical trials of rare diseases is sample size and sample selection. 
The small and heterogeneous study sample in the present work made it difficult to draw 
conclusions concerning the effects of the exercise intervention. Consequently, future 
studies on exercise regimes should be performed as multi-centre studies. National and 
even international cooperation and networking are therefore to be further developed. It 
would be interesting to explore facilitators for and barriers to physical exercise in 
people with DM1, to identify possible targets for interventions. Future studies are also 
needed to decide how exercise programmes should be designed for achieving optimal 
effect.  
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Appendix 
 
The modified ICF checklist 
* Categories added to the ICF checklist by 
the authors. 
 
List of 29 Body Functions  
b1. Mental functions 
b110 Consciousness (Daytime 
sleepiness) 
b114 Orientation 
b130 Energy and drive functions 
b134 Sleep 
b140 Attention 
b144 Memory 
b164  Higher-level cognitive functions 
b2.  Sensory functions and pain 
b210 Seeing 
b215* Functions of structures adjoining 
the eye (ptosis) 
b230  Hearing 
b280  Pain 
b3.  Voice and speech functions 
b310  Voice 
b320*  Articulation functions 
b4. Functions of the cardiovascular, 
haematological, immunological, 
and respiratory systems 
b410  Heart 
b435 Immunological (allergies, 
hypersensitivity) 
b440  Respiration (breathing) 
b445*  Respiratory muscle functions 
b450* Additional respiratory functions 
(coughing, blowing) 
b5. Functions of the digestive, 
metabolic and endocrine 
systems 
b510* Ingestion functions (chewing, 
swallowing) 
b515  Digestive 
b525  Defecation 
b540*  General metabolic functions 
(diabetes, insulin resistance) 
b555  Endocrine glands (hormonal 
changes) 
b6.  Genitourinary and reproductive 
functions 
b620  Urination functions 
b7.  Neuromusculoskeletal and 
movement-related functions 
b710  Mobility of joint 
b730  Muscle power 
b765 Involuntary movements 
(myotonia) 
b770*  Gait pattern functions 
 
 
 
 
 
 
 
b8. Functions of the skin and 
related structures 
b850* Functions of hair (baldness) 
List of 52 Activities and Participation 
d1.  Learning and applying 
knowledge 
d166*  Reading 
d170*  Writing 
d172* Calculating 
d175  Solving problems 
d2.  General tasks and demands 
d210  Undertaking a single task 
d220  Undertaking multiple tasks 
d230*  Carrying out daily routine 
d3.  Communication 
d310-
329  
Communicating – receiving 
d330-
349  
Communicating – producing 
d4.  Mobility 
d410* Changing basic body position 
d415* Maintaining a body position 
d430  Lifting and carrying objects, light 
objects 
d430  Lifting and carrying objects, 
heavy objects 
d440  Fine hand use (picking up, 
grasping) 
d445* Hand and arm use 
d4500* Walking short distances 
d4501* Walking long distances 
d4502* Walking on different surfaces 
d4503* Walking around obstacles 
d4551* Climbing 
d4552* Running 
d4600* Moving around within the home 
d4601* Moving around within buildings 
other than home 
d4602* Moving around outside the home 
and other buildings 
d465  Moving around using equipment 
(wheelchair, walker etc.) 
d470  Using transportation (car, bus, 
train, plane) 
d475  Driving (riding bicycle and 
motorbike, driving car, etc.) 
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d5.  Self-care 
d5100* Washing body parts 
d5101* Washing whole body 
d5102* Drying oneself 
d5201* Caring for teeth 
d5202* Caring for hair 
d5203-
d5204* 
Caring for finger and toenails 
d530  Toileting 
d5400* Putting on clothes 
d5401* Taking off clothes 
d5402* Putting on footwear 
d5403* Taking off footwear 
d550  Eating 
d560  Drinking 
d6.  Domestic life 
d620  Acquisition of goods and services 
(shopping) 
d630  Preparation of meals (cooking 
etc.) 
d640  Doing housework (cleaning 
house, washing dishes, laundry, 
ironing, etc.) 
d650* Caring for household objects 
d7.  Interpersonal interactions and 
relationships 
d710  Basic interpersonal interactions 
d720  Complex interpersonal 
interactions 
d8.  Major life areas 
d820  School education 
d830  Higher education 
d850  Remunerative employment 
d860  Basic economic transactions 
d870  Economic self-sufficiency 
d9.  Community, social and civic life 
d910  Community life 
d920  Recreation and leisure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of 23 Environmental factors 
e1. Products and technology 
e110 For personal consumption (food, 
medicines) 
e115  For personal use in daily living 
e120  For personal indoor and outdoor 
mobility and transportation 
e125  Products for communication 
e155  Design, construction and building 
products and technology of 
buildings for private use 
e3. Support and relationships 
e310  Immediate family 
e320  Friends 
e325  Acquaintances, peers, colleagues, 
neighbours and community 
members 
e340  Personal care providers and 
personal assistants 
e350* Domesticated animals 
e355  Health professionals 
e4.  Attitudes 
e410  Individual attitudes of immediate 
family members 
e420  Individual attitudes of friends 
e425* Individual attitudes of 
acquaintances, peers, colleagues, 
neighbours and community 
members 
e440  Individual attitudes of personal 
care providers and personal 
assistants 
e450  Individual attitudes of health 
professionals 
e460  Societal attitudes 
e5.  Services, systems and policies 
e525  Housing services, systems and 
policies 
e540  Transportation services, systems 
and policies 
e570  Social security, services, systems 
and policies 
e575  General social support services, 
systems and policies 
e580  Health services, systems and 
policies 
e590  Labour and employment services, 
systems and policies 
 
